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Diagnosis of nickel allergy is often based on _in vivo patch
testing. This thesis describes a lymphocyte transformation test
(LTT) in which soluble nickel sulphate (NiSO^) was used to
stimulate peripheral blood mononuclear cells (PBM) _iti vitro from
nickel sensitive individuals.
Sixty-six patch test positive patients, together with 46 non-
sensitive controls were studied using 0-20pg/ml NiSO^ in a 6 day
LTT; cells from 55 patients and 43 controls were also studied in a
7 day assay. Cells from 61/66 patients (92%) gave a stimulation
index (SI) of ^3 with 5pg/ml of nickel sulphate in a 6 and/or 7 day
assay. Cells from all 43 controls gave an SI <3. Cells from
patients and controls were stimulated equally by the mitogen Con A.
This indicates that using appropriate culture times and
concentrations of antigen, the LTT is both sensitive and specific
in confirming contact sensitisation to nickel.
The 6 day LTT was modified to study the accessory cell
function of plastic-adherent blood cells and epidermal cells. PBM
were subjected to plastic-adherence, incubation on nylon wool
columns and finally adherence to glass to obtain an enriched
population of T-cells which normally contained <0.5% MHC II+ cells
and was incapable of proliferation in the presence of either NiSO^
or Con A. Addition of plastic-adherent blood cells (containing 55%
MHC II+ cells) reconstituted the antigen-specific response in 16/18
experiments using cells from nickel-sensitive patients. In 15/16
experiments, enriched T-cells from non-sensitised controls
proliferated in the presence of Con A but not NiSO^ when they were
similarly reconstituted with plastic-adherent blood cells.
Epidermal cells, obtained from suction blisters, and
containing 2% MHC II+ cells also reconstituted or even enhanced the
response of enriched T-cells from nickel sensitive patients to Con
A or NiSO^. Epidermal cells from four controls reconstituted the
response of enriched T-cells to Con A only.
The role of MHC II molecules in controlling the response of T-
cells to NiSO^ and to Con A was studied using the 6 day LTT and a
number of monoclonal antibodies against HLA-DP, -DQ and -DR.
Antibodies against HLA-DR inhibited consistently the antigen-
specific response (82-96% inhibition) and normally inhibited (40-
98%) the response to Con A, both of PBM and enriched T-cells
reconstituted with plastic-adherent blood cells. At equivalent
antibody concentrations, an antibody against HLA-DP also inhibited
the response of PBM to nickel sulphate, but to a lesser extent (32-
58%). Antibodies against HLA-DQ and beta2microglobulin (a control
antibody) had no effect on the proliferation of PBM in response to
either NiSO^ or Con A.
In conclusion, these studies have shown that the LTT, using
5pg/ml NiSO^ in 6 and 7 day assays is an excellent method for
detecting nickel sensitivity, showing good correlation with the in
vivo patch test. The method has been adapted to demonstrate the
capacity of blood and epidermal cells to act as accessory cells,
and to assess the role of MHC class II molecules on the surface of
these cells in controlling the proliferation of T-cells in response
to both an antigenic and a mitogenic stimulus.
INTRODUCTION
The complex phenomenon of contact sensitivity or allergic
contact dermatitis (ACD) has been investigated for more than a
century. In 1840, Fuchs observed that only certain individuals
reacted against particular chemicals and his observations were
followed by skin testing to common chemicals including mercury
salts and soaps (Hebra, 1869; cited by Dupuis and Benezra, 1982).
However, Jadassohn is credited with establishing the concept of ACD
after reporting that the application of iodoform to the normal skin
of five sensitised (allergic) subjects reproduced their dermatitis
(1896).
Preliminary studies on ACD were carried out on human
volunteers experimentally sensitised to extracts of Primula leaves
(Low, 1924; Bloch and Steiner-Wourlisch, 1926), p-phenylenediamine
(Mayer, 1928) and 2,4-dinitrochlorobenzene (DNCB) (Wedroff, 1927,
1932; cited by Dupuis and Benezra, 1982). The discovery of a
suitable experimental animal model (the guinea pig) (Bloch and
Steiner-Wourlisch, 1930; Jadassohn, 1930; cited by Dupuis and
Benezra, 1982) has permitted extensive research into the
immunological mechanisms of ACD. Contact sensitivity has since
been induced in several animal species including mice, rats, dogs,
chickens and monkeys (Polak, 1980).
Work carried out by Landsteiner and his group greatly
contributed to the research into the mechanism of ACD. Firstly,
they established the importance of chemical structure in contact
sensitivity by demonstrating that low molecular weight substances
called haptens (MW 400-900 Da) require conjugation with protein
carriers before stimulation of the immune system can take place
(Landsteiner and Jacobs, 1935). Secondly, they confirmed the
existence of two types of immune reaction (humoral and cell-
mediated) by transferring contact sensitivity to picryl chloride
from a hypersensitive to a normal guinea pig using living lymphoid
cells, but not using serum (Landsteiner and Chase, 1942).
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In 1961, it was discovered that lymphocytes comprise two
functionally different populations; B-cells (bursa-equivalent
lymphocytes) which are the precursors of antibody producing plasma
cells and T-cells (thymus-dependent lymphocytes) which are
responsible for cell mediated immunity (Miller, 1961).
It is now well established that ACD is a delayed
hypersensitivity (type IV) reaction mediated by T-cells against
haptens which are absorbed through the skin.
The reaction can be divided into two phases, induction and
elicitation. During the induction phase hapten binds to protein
(possibly within the skin), forming an antigen which can be
recognised by hapten-specific virgin T-cells. These cells become
sensitised. They proliferate in the draining lymph nodes (Turk and
Oort, 1970) to produce memory and effector cells (Turk and Stone,
1963; cited by Polak, 1980).
The elicitation phase occurs when a sensitised individual
subsequently contacts the same hapten. The hapten again binds to
protein producing an antigen which can be recognised by the hapten-
specific effector T-cells. These cells secrete a number of soluble
substances (lymphokines) which attract and activate non-specific
mononuclear cells to the site of hapten application, amplifying the
response and causing a local inflammatory reaction.
During the last ten years, the mechanisms involved in antigen-
including hapten-) specific T-cell activation have been further
clarified, and the next section reviews this work in some detail.
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ANTIGEN-SPECIFIC T-CELL ACTIVATION
Established techniques to enrich T-cells and to produce T-cell
clones have been used to show that mitogen- or antigen-specific T-
cell activation requires the presence of another cell type (an
accessory cell). Requirements for T-cell activation will be
discussed as follows:-
T-cell subtypes and markers
Accessory cells. (1) cells with accessory function
(2) requirements:- MHC restriction
Antigen processing
Interleukin-1 production
T-cell receptor and antigen-specific T-cell activation.
T-Cell Subtypes and Markers
All human T-cells express receptors for sheep red blood cells
(CD2) and the CD3 antigen; however, T-cells can be divided into 4
functional subgroups:-
T^- helper cells - stimulate the immune response
Tg- suppressor cells - depress the immune response
T - cytotoxic cells - kill virally infected or foreign cells
Tdh ~ delayed hypersensitivity cells - secrete lymphokines
(Nash and Gell, 1981)
In addition, 2 phenotypic populations exist:-
CD4* W
CD8* (Ts, Tc);
although the phenotypes CD4+ and CD8+ may overlap between the
functional groups (Spits et al., 1983).
There is no good in vitro model of delayed hypersensitivity (DH),
but DH function is normally correlated with results obtained using
a lymphocyte transformation test (LTT), which measures cellular
incorporation of radioactive thymidine into newly synthesised DNA,
which precedes the proliferation of T-cells in response to the
presence of hapten or antigen.
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Accessory Cells
Many cell types have been shown to act as accessory cells in
lymphocyte transformation. Examples are shown in Table 1.1.
The earliest experiments on accessory cell function were
carried out using macrophages; therefore, the macrophage will often
be used as an example of an accessory cell during this thesis.
Furthermore, initial experiments were carried out primarily on mice
and guinea pigs and not on humans.













In 1973, Rosenthal and Shevach showed that antigen-specific T-
cell proliferation required histocompatibility between the
accessory cells (macrophages) and the T-cells. It is now firmly
established that most T-cells will recognise antigen only when it
is associated on the cell surface with a self molecule encoded by
the Major Histocompatibility Complex (MHC); a phenomenon known as
MHC restriction. In man, the MHC codes for human leucocyte
Key Reference
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antigens (HLA). The functionally different T-cell subclasses vary
with respect to the type of molecule they recognise:- Tc are
restricted by class I molecules (Zinkernagel and Doherty, 1975);
and are restricted by class II molecules (Thomas et al,, 1977);
however, these subpopulations probably overlap (Braciale, 1987).
The Major Histocompatibility Complex
In man the MHC represents approximately one thousandth of the
genome and is situated on the short arm of chromosome 6. It was
named the MHC because the HLA molecules encoded were first
recognised as classical transplantation antigens on the cell
surface. There is no allelic exclusion of MHC antigens and they
are expressed co-dominantly. The structure of the complex is
summarised in fig 1.1 and comprises several loci.
HLA-A -B -C : code for the MHC class I molecules
HLA-D : codes for the MHC class II molecules
In addition, there are loci coding for MHC class III molecules
which are components of the complement cascade. Only class I and
class II molecules are involved in T-cell antigen recognition and
will be discussed below.
Class I
Class I HLA antigens (fig 1.3) are found on almost all
nucleated cells and comprise a 45kDa transmembrane glycoprotein
(alpha chain) in non-covalent association with an invariant 12kDa
protein, beta2 microglobulin. Alpha chains are encoded in the MHC,
micro-globulin at a locus on chromosome 15. Expression of the
alpha chain requires the association with beta2 microglobulin.
Class II
Class II HLA antigens (fig 1.4) have a more limited tissue
distribution than class I molecules. They are expressed on cells
such as macrophages, B-lymphocytes and dendritic cells, which are
cells involved in interactions with T-lymphocytes during immune
responses. Class II molecules consist of two transmembrane
glycoproteins- a 33kDa alpha chain and a 28kDa beta chain. Before
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The HLA complex is situated on the short arm of chromosome 6.
Fig 1.2 Map of the human HLA-D Region
I
A
DP [ DZ/DO [ DQ I DR-
£ -C £ d- «*- p P p p
Expressed genes are depicted as filled boxes, pseudogenes by cross-
hatching, and genes of undetermined status are blank.
From Trowsdale (1988)
Fig 1.3
Class I MHC Antigen
Fig 1.4
Class II MHC Antigen
S-S = Disulphide bonds between cysteine residues.
•- = Carbohydrate side chain.
/S^M = ^microglobulin.
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insertion into the membrane, the class II molecules are associated
with a third invariant gamma chain (Kvist e_t , 1982).
The map of the HLA-D region (fig 1.2) is still provisional.
The only class II gene products presently known to be
expressed on the cell surface are HLA-DP, -DQ, and -DR. Evidence
exists that antigen forms a complex with the MHC II molecule
(Babbitt e_t _al. , 1985); however, the degree of specificity with
which antigen binds MHC II molecules is uncertain (Finnegan and
Berzofsky, 1986). An antigen binding groove may be present in MHC
II molecules (Bjorkman et al., 1987).
Experiments using antibodies directed against class II
molecules indicate that HLA-DR is required for antigen-specific
proliferation of T-cells, and preliminary evidence suggests that
the expression of HLA-DQ may be important in suppressor cell
activation (Festenstein and Oilier, 1987). The biological
significance of HLA-DP awaits clarification.
Expression of MHC II antigens on antigen presenting cells
(APC) is not constant. Substances released during contact
sensitivity reactions can alter MHC II expression. Prostaglandins
are important mediators of inflammation, and prostaglandins El and
E2 diminish MHC II expression (Snyder et al., 1982). Conversely,
activated T-cells release gamma-interferon (Schober et_ _al. , 1984)
which has been shown to enhance (Berman e_t _al. , 1985) or induce
(Basham et al., 1984) MHC II expression in different cell types.
However, the expression of class II molecules on a cell
surface is not the only requirement for T-cell activation.
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Antigen Processing
Most complex antigens require processing before presentation
to T-cells. Antigen is taken up by phagocytic cells, endocytosed
and then fragmented. The antigen is then recycled to the cell
surface in a form capable of association with MHC II molecules
(Allen and Unanue, 1984). The MHC II molecule may bind the
antigens, stabilise them in the cell membrane and prevent
proteolytic degradation (Werdelin, 1987). Some of the
immunologically relevant antigen remains within the accessory cell
(Ellner et_ al., 1977). Haptens, being low molecular weight
substances, may not require antigen processing.
Interleukin 1 Production
Accessory cells must also be capable of producing a low
molecular weight molecule, Interleukin 1 (IL-1), which is antigen-
non-specific (Aarden e_t _al.* > 1979). Interleukin 1 is produced by
most cell types (Oppenheim £t^ £l_., 1986) and acts as a maturation
signal, preparing T-cells to respond to antigens or secondary
mediator signals (Mizel, 1982). Unstimulated macrophages release
little IL-1; macrophage IL-1 production is probably activated by
the presence of T-cells plus antigen or mitogen. Interleukin 1
release may be stimulated further by T-cells after their
maturation, thus amplifying the initial phase of the immune
response. Mitogens (which non-specifically cross-link T-cell
receptors) can activate T-cells in the absence of accessory cells
if IL-1 is present (Farrar _et al., 1980); however, T-cell
stimulation by IL-1 in antigen-specific responses is totally
dependent on the presence of accessory cells (Mizel and Ben-Zvi,
1980).
MHC II Antigen Expression In Disease States
Within the last 7 years it has been demonstrated that several
types of epithelial cell which do not normally express MHC II
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antigens, become MHC II positive at sites of inflammation caused
by certain disease states, eg thyroid cells in autoimmune
thyroiditis (Hanafusa £t_ al_., 1983) and keratinocytes in graft
versus host disease (Mason et^ al^., 1981). Thyroid follicular
epithelial cells expressing class II molecules in thyroiditis
possess the ability to present peptide antigen to cloned T-cells,
and the presence of these "aberrant" MHC II molecules may be
important in perpetuating or even initiating auto-immune disease
(Londei e_t _al_. , 1984). Keratinocytes express MHC II antigens in
many dermatoses including graft versus host disease, mycosis
fungoides, lichen planus and contact dermatitis, in which there are
also many activated T-cells present. Cultured keratinocytes have
been shown to express MHC II antigens when incubated with gamma-
interferon (Basham £_t al_. , 1984) and it is probable that
keratinocyte MHC II expression is mediated by gamma-interferon
released by T-cell infiltrates (Nickoloff e_t al_., 1985).
Antigen-Specific T-Cell Activation
The structure of the T-cell receptor has been established in
studies using antigen-specific T-cell clones and monoclonal
antibodies directed against their membrane molecules (Acuto and
Reinherz, 1985). It is now known that the T-cell receptor exists
as a surface complex comprising a 90kDa di-sulphide-linked
heterodimer (Ti molecule) and three monomorphic molecules (gamma,
delta and epsilon) which make up the CD3 complex (fig 1.5).
Furthermore, the CD4 antigen, a marker specific for T^ and T^
cells, may also be in physical association with the T-cell receptor
complex (Saizawa et al., 1987). The Ti alpha and beta chains (fig
1.6) are immunoglobulin-like and confer variability to a T-cell;
transfection experiments indicate that the alpha and beta genes are
sufficient to code for MHC-restricted antigen recognition (Dembic
£t^ _al/, 1986). More recently, a second T-cell receptor comprising
a gamma and delta chain has been identified on CD4~ CD8~ cells.
However, the role of this receptor (discussed by Owen, 1988) is
unknown.
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Fig 1.5 T-Cell Receptor Complex (Ti-CD3)
Ti oc and /3 subunits are held together by S-S bonds and are
associated with the gamma subunit of the CD3 molecule.
From Alcover e_t a_l. (1987).
Fig 1.6 Structure of the Ti alpha and beta chains
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It is thought that the following events occur during T-cell
activation (fig 1.7)
(a) The Ti molecules recognise MHC II and antigen. The CD4
antigen may bind to a non-polymorphic portion of MHC II and
stabilise the reaction. Interleukin 1 is secreted by the APC.
(b) The CD3 complex sends an activation signal across the
lipid bilayer; ion channels in the plasma membrane are opened and
calcium enters down its concentration gradient (Alcover ejt al_.,
1987). The alteration in the intra-cellular cations effects gene
transcription.
(c) The number of surface antigen-specific receptors
decreases.
(c and d) Activation stimulates endogenous Interleukin 2 (IL-
2) production and secretion, and the expression of IL-2 receptors
on the same clones. Interleukin 2 also stimulates the release of
T-cell gamma-interferon which enhances MHC II molecule expression
on the APC.
(e) Once a critical number of receptors have bound IL-2, DNA
synthesis and mitosis of the cell occur.
(f) After antigenic stimulation ceases, T-cells re-express the
Ti-CD3 complex, and the number and affinity of IL-2 receptors
decrease.
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Fig 1.7 Antigen-Specific T-Cell Activation
Ti recognises MHC II and
antigen.












Cells secrete IL-2 and
gamma interferon.
IL-2 binding permits DNA
synthesis and mitosis







Two plant lectins (proteins which specifically bind certain
sugars), Concanavalin A (Con A) and phytohaemagglutinin (PHA), are
T-cell mitogens and are commonly used in _in vitro transformation
assays. However, the mechanisms of antigen-specific and mitogen-
induced T-cell activation may not be identical.
Some experiments indicate that accessory cells are
unnecessary for T-cell activation by these mitogens. Investigators
have shown that the presence of serum in culture may replace some
accessory cell function (Persson et_ al_., 1978) and it is possible
that the serum contains soluble factors released by monocytes
(including MHC II molecules and IL-1). The reducing agent 2-
mercaptoethanol (2-ME) has also been shown to stimulate Con A-
induced proliferation of enriched T-cells (Roosnek et al., 1985).
However, it has been suggested that the relationship between
monocytes and thiols is an _in vitro phenomenon.
Conversely, many reports indicate that a mitogen-induced
proliferative response is dependent on the presence of accessory
cells (Hedfors et_ al., 1975; Rosenstreich et^ al., 1976; Habu and
Raff, 1977). In the presence of mitogenic concentrations of
lectin, cross-linking of cell membrane molecules occurs (Con A
binds alpha-D mannose and alpha-D glucose) but the exact
requirement for accessory cells in Con A-induced T-cell
proliferation is unknown.
Cell-cell contact may be a prerequisite for T-cell
activation. Mitogenic amounts of lectin do not cluster cells and
it has been suggested that accessory cells may be required to
induce aggregation (Roosnek et_ al., 1985). However, it is unlikely
that this is the reason for the accessory cell requirement in
mitogen-induced proliferation because neuraminidase treatment of
cells (which removes the cells' negative charges, permitting
agglutination) does not mediate T-cell proliferation (Hunig, 1983).
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Addition of IL-1 to enriched T-cells incubated with PHA does
not induce T-cell activation (Chu et al., 1985). This indicates
that the release of IL-1 by accessory cells is not the only factor
required for T-cell activation.
Finally, Kimura and Ersson (1981) have shown that lectins are
raitogenic only if they are capable of binding to MHC II molecules.
They suggested that mitogen-induced T-cell proliferation is similar
in principle and requirements to antigen-specific T-cell
activation. The recognition of mitogen by T-cells (without the
need for 'antigen processing' (Chu et al., 1985)) may therefore be
very similar to hapten-specific T-cell activation which as
previously mentioned is unlikely to require antigen processing by
an antigen presenting cell.
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THE SKIN IMMUNE SYSTEM
The skin is important in protection from the environment
because it functions as a physico-mechanical barrier. Furthermore,
the skin may play an important role in the immune system. In 1978,
Streilein hypothesised the existence of skin-associated lymphoid
tissues (SALT). Five years later, he summarised the evidence for
SALT as follows
(1) Specialised antigen presenting cells are found in the
epidermis (Langerhans cells).
(2) Antigen recognition by lymphocytes can take place in the
skin.
(3) Some recirculating T-cells preferentially infiltrate the
skin (especially the epidermis).
(4) Draining lymph nodes accept immunological signals derived
from the skin.
(5) Cutaneous immunity can be regulated by signals released by
skin cells.
(Streilein, 1983).
It is now known that a number of immunologically relevant
cells may be found in the skin (Table 1.2).
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Table 1.2 Skin Cells With or Without Immunological Relevance
















Vascular endothelial cells Sebocytes
Lymphatic endothelial cells Neural receptor cells
T-cells Smooth muscle cells
(Bos and Kapsenberg, 1986)
Dendritic Cells Important In the Human Immune System
Dendritic antigen presenting cells in the human skin include
Langerhans cells (LC) and indeterminate cells (which may be
immature LC). In mice, two other epidermal cell types, the Thy-
l+cell (Tschachler £t_ jil^., 1983; Bergstresser et al., 1983) and an
ultraviolet radiation-resistant cell (Granstein et al., 1984) have
been described in the epidermis. These two murine cell types may
be capable of down-regulating the immune response (Bigby e_t al.,
1987; Granstein _al. , 1984). Equivalent cell types have not yet
been found in man.
Epidermal Antigen Presenting Cells
Before the discovery that gamma-interferon induced keratinocyte
MHC II antigen expression, it was assumed that only one epidermal
cell type, the Langerhans cell, was capable of antigen
presentation.
Langerhans Cells
In 1868 Paul Langerhans first described a population of
dendritic epidermal cells after staining skin with gold chloride to
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study nerve cells. Langerhans cells are found in most squamous
epithelia and comprise approximately 3% of epidermal cells.
However, their number varies with the anatomical site (Horton e_t
al., 1984). Langerhans cells can be stained with osmium and DOPA
and contain adenosine triphosphatase, alkaline phosphatase and
cholinesterase (Rowden, 1981). In 1981, Poppema et_ al. showed that
LCs express the CD1 marker. Using electron microscopy, LCs were
shown to possess a distinctive cytoplasmic granule (the Birbeck
granule) which, in thin sections, is rod-shaped but may have a
vesicle at one end, giving the appearance of a tennis racquet
(Birbeck ^_t al., 1961).
An immunological function for the LC was suggested after the
discovery of surface receptors for IgG Fc and complement C3 (Stingl
et al., 1977). Studies carried out on lymph nodes draining sites
of allergen application have suggested that LCs carry cutaneously
applied allergen to the regional lymph nodes for presentation to T-
cells (Godfrey and Baer, 1971; Botham et^ _al_. , 1987). The
expression of MHC II molecules (Rowden £t_ a^., 1977) together with
an ability to produce IL-1 (Sauder e_t _al_. , 1984) make it likely
that LCs are antigen presenting cells.
In vitro assays have assessed the ability of epidermal cells to
present antigen and mitogen to T-cells. Both crude epidermal cell
suspensions (Stingl et al., 1978; Braathen and Thorsby, 1980) and
enriched LCs (Bjercke et^ al., 1984) have accessory cell function.
Keratinocytes
Keratinocytes (90-95% of the epidermal cell population) have
recently been shown to express MHC II antigens in certain disease
states and in the presence of gamma-interferon (Basham et_ al.,
1984). Furthermore, cultured keratinocytes produce soluble factors
including epidermal cell-derived thymocyte activating factor (ETAF)
which is a molecule equivalent to IL-1 (Sauder et_ al., 1982). The
ability of MHC II positive keratinocytes to present antigens and
mitogens has been studied. Nickoloff et al. (1986) showed that
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HLA-DR+ keratinocytes permitted T-cell activation but mitosis did
not occur. They suggested that the keratinocytes were secreting an
inhibitory molecule. Nishioka ^t al. (1987) failed to stimulate
antigen-specific T-cells using MHC II positive keratinocytes;
however, addition of IL-2 permits lymphocyte transformation
(Morhenn and Nickoloff, 1987). Suction blisters removed from
tuberculin-reactive skin (in which most keratinocytes are
expressing HLA-DR) were more effective at presentation of PPD than
suction blisters from control skin (Tjernlund and Scheynius, 1987).
However, removal of LCs from these epidermal cell suspensions
prevents accessory cell function (Scheynius e_t al_., 1988), which
may indicate synergy between LCs and HLA-DR+ keratinocytes in
antigen presentation. Further work is required before the role of
MHC II positive keratinocytes in antigen presentation is defined.
THE INFLAMMATORY REACTION IN ACD
In ACD, activated T-effector cells release a variety of
substances (lymphokines) which recruit inflammatory cells to the
site, activate them and keep them at the site. The release of
substances including lysosomal enzymes, prostaglandins (especially
the vasodilator prostaglandin E2) and complement factors by both
the inflammatory infiltrate and the activated T-cells contribute to
the clinical appearance of ACD.
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ALLERGIC CONTACT DERMATITIS IN HUMANS
In its acute phase, a dermatitis (eczema) reaction is
characterised by redness, oedema, papules, vesiculation, exudation,
crusting and itch (fig 1.8). In chronic dermatitis, whether due to
atopy (fig 1.9) or repeated contact with an allergen, the involved
skin may become thickened, lichenified (an increase in skin
markings), fissured and pigmented.
ACD may develop at any age but is uncommon in children. Some
strongly allergenic substances induce allergy in the majority of
people exposed to them (eg poison ivy); however, in general only a
small number of people will be sensitised after contact with an
allergenic chemical. At least 5 factors influence the induction of
sensitisation to a chemical (Fregert, 1981).
1)sensitisation capacity of the chemical
2)skin damaging factors (eg skin disease, hydration, dryness)
3)environment of the skin surface (eg temperature, humidity)
4)exposure (eg concentration, occlusion)
5)genetic factors
The extent of dermatitis in an allergic subject is influenced
by similar factors (Fisher, 1975)
Causative Agents
Thousands of substances have been described as contact
allergens; however, only 20-30 substances cause most cases of ACD
(Fregert and Bandmann, 1975). Aetiological agents may be
identified by a procedure known as patch testing.
The value of patch testing patients suspected of having ACD
was established by Bonnevie in 1939, twenty eight years after Bloch
described a detailed procedure for applying allergens to the skin
of normal and sensitised subjects (cited by Cronin, 1980). Patch
testing is now a standardised procedure which allows comparison
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Fig 1.8 Acute Vesicular Contact Dermatitis
(caused by a rubber glove)
- 21 -
between different patients and different centres. The
Dermatology Department at the Royal Infirmary, Edinburgh routinely
uses the European Standard Battery (Table 1.3) recommended by the
International Contact Dermatitis Research Group (ICDRG). When
necessary, additional batteries related to occupation, clothing or
hospital treatment are included. Patients may also be advised to
bring items suspected of causing ACD for patch testing.
Table 1.3 European Standard Battery




Wool alcohols 30.0% Cobalt Chloride 1.0%
Mercapto rubber mixture 1.0% Balsam of Peru 25.0%








PPD rubber mixture 0.6%
Naphthyl rubber mixture 1.0% Turpentine peroxides 0.3%
Colophony 20.0% Formaldehyde 2.5%
Caine mix 3.0% Primin 0.01%
'ff
Contents of the mixtures are in Appendix I (pages 173-74).
Patch testing is described in the Materials and Methods
section (page 43).
Marked variations exist in the prevalence of ACD to different
substances in different populations, depending on the population
studied (eg male/female) and the changing exposure of allergens.
However, nickel compounds and rubber compounds remain two of the
most common causes of ACD (Fisher, 1975; Vestey et al., 1986). It
was because of patient availability that the studies reported in
this thesis on in vitro requirements of antigen presentation in ACD
were performed using nickel-sensitive patients.
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NICKEL
Nickel was first isolated in 1751 and is a silver-white
transition metal, which can be polished to give a bright gloss.
The word 'nickel' is derived from 'kupfernickel' (devil's copper)
originally used by German copper miners (1694) to describe
niccolite (nickel arsenide) which visually resembles copper and
when heated produces toxic fumes reminiscent of the Devil at work.
Nickel is the 24th most common element in the Earth's crust
and has a widespread distribution in the environment. Certain
plants and animals have an absolute requirement for nickel (Anke et
al. , 1984). Little is known about its biological functions in
animals or man; however, nickel may be concerned with the
maintenance of the structure and function of cellular membranes
(Doll, 1984).
Man ingests 100-600pg of nickel per day; a deficiency state
has never been identified. Foodstuffs possessing a high nickel
content include legumes, leafy vegetables, mushrooms, chocolate,
nuts and baking powder. Nickel may also be transferred to the diet
by using nickel-containing kitchen equipment (Christensen and
Moller, 1978). Less than 10% of ingested nickel is absorbed into
the blood stream; 70% of this is then excreted via the kidneys; the
remaining nickel is stored in body tissues and retained for
approximately 200 days (Bennett, 1984). Five nickel-binding
fractions have been described in serum (Silvennoinen-Kassinen e^t
al., 1987) including
1) Alpha2-macroglobin-bound nickel (nickeloplasmin)
2) Albumin-bound nickel (N^-terminal)
3) Amino acid (L-histidine) bound nickel
(Lucassen and Sarkar, 1979).
L-histidine has a greater affinity for nickel than HSA.
Nickel exchange and transfer between these two binding fractions is
mediated by the complex albumin-nickel-L-histidine, permitting
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albumin-nickel to transfer the metal ion to a low molecular weight
constituent of serum, which could then transport nickel into cells
(Sarkar, 1984).
Nickel is a strong corrosion-resistant metal and therefore has
a wide range of applications. However, although nickel is an
industrially useful metal, under certain circumstances contact with
this element is hazardous.
Carcinogenicity and Mutagenicity
An increased cancer risk among nickel workers was first
suspected in 1932; however,the specific cancer inducing mechanism
of nickel is not yet understood. Studies have shown that
carcinogenicity of nickel compounds is inversely proportional to
water solubility (Dewally, 1984) and directly proportional to
cellular uptake (Costa and Mollenhauer, 1980). Nickel (probably as
an ion) crosses the cell membrane, and after deposition in the
nucleus and nucleolus, can form a complex with DNA (Ciccarelli and
Wetterhahn, 1984).
Chromosomal damage in the leucocytes of nickel workers after
short term culture has been described (Waksvik and Boysen, 1982)
and white blood cells incubated with different nickel salts have
undergone DNA strand breaks, sister chromatid exchange and
chromosome aberrations (Saxholm, 1984).
Acute Toxicity
The chief industrial hazard of nickel is exposure to nickel
carbonyl which can be fatal, with major lesions in the lungs and
brain.
Embryotoxicity
Nickel compounds can penetrate the placenta and enter the
foetus. Teratogenic effects result from a direct toxic effect on
the foetus. Nickel may cause changes in the mitotic apparatus,
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resulting in cell death at critical times of development (Leonard
and Jacquet, 1984).
Immunotoxicity
Nickel compounds can adversely affect the immune system of
experimental animals and it has been postulated that nickel-induced
suppression may be related to nickel carcinogenicity (Smialowicz e_t
al. , 1985).
Immediate Type Hypersensitivity
The mechanism by which IgE antibodies initiate asthma is well
understood and a number of allergens (eg grass pollens and the
faecal pellets of the house dust mite) are recognised as causative
agents. However, bronchial asthma induced by nickel dust aerosols
is rare. The first case was described by McConnell ^t al. in 1973,
and in 1982 a further two cases were reported (Malo et^ al. , 1982;
Block and Yeung, 1982). Patients can be diagnosed by inhalation
challenge with nickel sulphate, positive skin prick tests and by a
nickel-HSA radioallergosorbent test. The antigenic determinant in
this allergy is nickel-HSA (Dolovich e_t al. , 1984).
Cases of systemic immediate type hypersensitivity after
iatrogenic nickel exposure have been reported. Patient symptoms
included generalised itch and widespread urticaria (McKenzie ejt
al., 1967) and swollen face, lips and hands accompanied by wheezing
(Fisher et _al., 1982).
Contact Dermatitis
Before 1930, nickel dermatitis was primarily an occupational
disease, particularly in the plating industry. Cutaneous exposure
to dissolved nickel may still cause dermatitis in certain
occupations including electro-plating, hairdressing and domestic
cleaning; however, the increased presence of nickel in the everyday
environment (Table 1.4) has made nickel the most common sensitising
agent.
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Metallic nickel is usually the sensitiser; however, the water
soluble salts, nickel chloride (NiC^) and nickel sulphate (NiSO^)
are also strong sensitisers (Cronin, 1980). The sensitisation
potential of nickel salts was investigated in the 1960's using a
'maximisation' procedure; the skin was damaged by occluding the
irritant sodium lauryl sulphate with the sensitiser for 5 periods
of 48 hours (with 24 hour intervals between application). Using
this method, Kligman (1966) attempted to sensitise 25 healthy
subjects using 10% NiSO^. Following challenge with 2.5% NiSO^,
responses were seen in 12 individuals. Nickel sulphate is now
classified as a grade 3 sensitiser (Kligman, 1966) (grade 1 = weak
sensitiser, 0-8% sensitisation (eg pure soap); grade 5 = extreme
sensitiser, > 84% sensitisation (eg p-phenylenediamine). Once
sensitisation to nickel has been acquired, it is probably permanent
(Calnan, 1956).
Table 1.4 Examples of Articles Containing Nickel
Clothing Zips, suspenders, bra straps, jeans
Experiments have been carried out to study nickel's absorption
through the skin. The barrier to penetration is the stratum
corneum. Percutaneous uptake appears to be mainly through sweat
ducts and hair follicles (Wells, 1956). Absorption is probably
slow. Using surgically removed skin, Fullerton et al. (1986) have
suggested that nickel takes approximately 50 hours to permeate the







Earrings (pierced/clip on), necklaces,
rings, watches, bracelets.
Kitchen utensils, dishwashers, washing
machines, vacuum cleaners.
Coins, keys, doorknobs, eyeglass frames,
razors.
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Occlusion of skin _rn vivo will produce friction, heat and
sweat, all of which increase the penetration of nickel. Synthetic
sweat solutions can leach nickel from various materials (Katz and
Samitz, 1975) and temperature elevation increases nickel release
from some coins and jeans buttons (Menne and Solgaard, 1979).
Sensitivity to nickel is commonly investigated by patch
testing with 5% nickel sulphate in petrolatum, a concentration
which rarely sensitises (Agrup, 1968), but which may be mildly
irritant to some patients. Patch testing with 2.5% nickel sulphate
may fail to detect 20% of sensitised patients (Cronin, 1980). A
proportion of nickel-sensitive patients may have associated allergy
to two other transition metals, cobalt and chromium. Approximately
one third of nickel reactive women and one sixth of men also
respond to cobalt. One tenth of nickel reactive men also react
against chromium, but joint nickel-chromium reactivity in women is
rare (1%), (Cronin, 1980). The three transition metals are not
cross-reactive, but they occur together in several compounds and
concomitant sensitisation may take place (Fregert, 1981).
In many countries nickel is the commonest sensitiser in the
female (Cronin, 1980). Various studies have reported incidences of
sensitivity between 8% and 15% in women and between 1% and 3% in
men. In 1979 Peltonen undertook the first study of nickel
sensitivity in the general population (ie not a population
attending clinics). Nine hundred and eighty subjects above the age
of 10 were patch tested with 5% nickel sulphate. Eight per cent of
the females had positive patch tests and 0.8% of the males. It has
been suggested that more females are allergic to nickel than males
because of repeated exposure from jewellery, clothing and stainless
steel kitchen equipment. Evaluation of 185 materials (using the
maximisation procedure for identifying contact allergens) indicated
that sex differences, in the prevalence of sensitisation, reflected
previous exposure (Leyden and Kligman, 1977). During the last
twenty years the age of the onset of nickel allergy in women has
decreased from 30-50 years to 11-20 years (Cronin, 1980). A
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relationship between nickel sensitivity and ear piercing (which has
become popular in recent years, particularly in younger women) has
been shown by Larsson-Stymne and Widstrom (1985), who studied 960
schoolgirls and found that the prevalence of nickel allergy among
girls with pierced ears is 13% and in those without pierced ears
Different clinical forms of nickel dermatitis, have been
described.
1) Localised dermatitis at an area in direct contact with
nickel (see Table 1.5, figs 1.10 & 1.11).







Metal pins held in mouth,
metal lipstick case.
Clasp of necklace, zipper.
Medallions, buttons.
Zipper.
Wire support of bra cup.
Buttons on jeans.
Handles of doors, handbags.




















Dorsum of foot Metallic eyelets of shoes.
Postoperative site Screws, bolts, plates in ortho-
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Localised Dermatitis at Areas in Direct Contact with Nickel
Fig 1.10 Jewellery Dermatitis
Fig 1.11 Allergy to Nickel in Jean Studs
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2) Secondary eruption of varying severity - initially
considered to be unrelated to nickel contact but may result
from inadvertent nickel contact (Fisher, 1975). Secondary
spread is usually eczematous and often symmetrical; however
non-eczematous reactions (eg urticaria or generalised itch)
may occur.
3) Hand dermatitis - occurring, at some time, in
approximately 40% of nickel-sensitive women (Menne e_t al.,
1982). Eight to 11% of all cases of hand eczema are caused by
nickel sensitivity; however, atopy, wet work and exposure to
irritants and sensitisers may also predispose an individual to
hand dermatitis (Rystedt, 1985; Fregert, 1975).
Hand eczema has a poor prognosis and presents in many patients
as pompholyx (Christensen and Moller, 1975a) which is a recurrent
vesicular eruption primarily located on the palms, and volar
aspects and sides of the fingers. Christensen and Moller (1975b)
suggested that pompholyx could be perpetuated by oral nickel
ingestion after aggravating hand eczema with 5-6mg nickel.
However, lower doses do not exacerbate pompholyx (Gawkrodger ^t_
al., 1986). The exact role of dietary nickel in aggravating nickel
dermatitis has not been determined but a diet intended to reduce
the daily intake of nickel may improve some cases of nickel
dermatitis (Veien et_ jl_. , 1985).
A low nickel diet is restrictive and is not suggested in the
management of all cases of nickel dermatitis. Patients are,
however, informed of the need for good skin care (particularly hand
care) and instructed to reduce external nickel contact (eg
varnishing jeans buttons or covering them with material).
Free (allergenic) nickel in metallic objects can be detected
using the dimethylglyoxime (DMG) spot test
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A few drops of 1% dimethylglyoxime in alcoholic
solution plus a few drops of 10% ammonium hydroxide
solution produce a strawberry red insoluble salt in the
presence of available nickel (Fisher, 1975).
Sites of chronic dermatitis are commonly treated with topical
corticosteroids to alleviate itching and inflammation.
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METHODS FOR THE DETECTION OF NICKEL HYPERSENSITIVITY
In Vivo Detection
At present, a diagnosis of nickel sensitivity is based on
patch testing with 5% nickel sulphate in petrolatum, often with a
battery of other allergens, and this concomitant patch testing may
lead to false positive results (Mitchell, 1977). In addition,
patch testing may occasionally sensitise non-allergic individuals
(Agrup, 1968) and should be carried out when the patient's back is
free of eczema (Mitchell, 1975).
Difficulties may be encountered when interpreting patch test
sites. Patch testing may cause irritant reactions (fig 1.12) and
these may be mistaken for allergic reactions. Patients with atopic
eczema may produce false positive pustular reactions to nickel
sulphate patch tests (Fisher, 1975).
Finally, patch testing requires patient attendance at the
hospital three times in one week, and can aggravate a patient's
previous or existing dermatitis. The patch test reactions (with
itch) may cause discomfort to the patient and occasionally patch
testing may cause the 'angry back syndrome' (Mitchell, 1975) (fig
1.13).
Therefore an _iri vitro method for detecting nickel sensitivity
would possess some advantages. However, it then becomes necessary
to obtain blood samples from patients, which can be unpleasant for
the patient and is also potentially hazardous to both clinicians
and laboratory workers.
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Fig 1.12 Difficulties Encountered when Interpreting Patch Tests
Patch test reactions
Top left = irritant Top Middle = +? Bottom Right = ++
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In Vitro Assays
Three assay methods have been described for detecting nickel
sensitivity _in_ vitro.
(1)Leucocyte Procoagulant Activity
The blood coagulation system is involved in the earlier stages
of a delayed hypersensitivity reaction. Macrophages, immobilised
by lymphokines (including migration inhibition factor (MIF)), are
surrounded by fibrin, which induces macrophage production of
plasminogen activator. In addition, activated T-cells secrete a
lymphokine to induce monocyte procoagulant activity. An _in_ vitro
method to determine procoagulant activity was first described in
1982 (Geczy and Meyer) and has been used in preliminary experiments
to identify nickel-sensitive patients (Aldridge e_t _al. , 1985). Ten
out of twelve nickel-sensitive patients could be discriminated from
9/9 controls. The two patients who did not respond had had
quiescent disease for several months, but still gave positive patch
test reactions. Therefore, detection of nickel sensitivity using
this assay probably requires currently active disease.
(2)Macrophage Migration Inhibition Test
Migration inhibition factor (MIF) was the first lymphokine to
be described, and can be detected 4-6 hours after lymphocyte
activation _in vitro. The macrophage migration inhibition test
(MMIT) assays the release of antigen-induced MIF from activated T-
cells. To detect nickel sensitivity, supernates from nickel-
activated or non-stimulated T-cells are incubated with monocytes or
macrophages, and the ability of the cells to migrate through
agarose or from a capillary tube is measured.
Lymphokine release is thought to represent an important step
in the development of delayed hypersensitivity reactions; however,
results obtained in the MMIT using the antigen nickel sulphate have
been inconsistent (Mirza et_ al., 1975; Nordlind and Sandberg,
1983). Combining the MMIT with another _iii vitro assay, the
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lymphocyte transformation test (LTT) may provide a reliable
diagnosis in most patients tested for nickel allergy (von Blomberg-
van der Flier et al., 1987).
(3)Lymphocyte Transformation Test
Studies on the Jul vitro activation of lymphocytes by specific
antigens or non-specific mitogens (eg the lectins Concanavalin A
(Con A) and phytohaemagglutinin (PHA)) with associated
transformation into blast cells began in the late 1950s. It took
another 15-20 years for the presently used lymphocyte
transformation test (LTT) to be developed.
Method Development
Initial lymphocyte transformation studies were hampered by
difficulties in obtaining leucocytes from whole blood. Preliminary
techniques utilised the ability of PHA to agglutinate erythrocytes
which could then be separated from leucocytes by centrifugation
(Hungerford ^t al., 1959). However, PHA is a T-cell mitogen,
therefore this method was useful only for investigating lymphocyte
stimulation by PHA.
Lymphocyte enrichment was later obtained by methods involving
gelatin (Coulson and Chalmers, 1964), passage through glass wool
(Brandt et_ a_l., 1962) or glass beads (Schrek and Stefani, 1964).
Also, a magnet was used to remove cells which had phagacytosed non¬
toxic carbonyl iron (Carstairs, 1962). The removal of the
phagocytic cells prevented antigen-specific lymphocyte trans¬
formation (Oppenheim ej^ a_l., 1966; cited by Pentycross, 1968)
because of the now recognised requirement for accessory cells
(which include monocytes).
At present, the most frequently used method for obtaining
mononuclear cells is density sedimentation by centrifugation in
Ficoll-sodium metrizoate (Ficoll-Paque) according to Boyum (1968);
erythrocytes and neutrophils are pelleted, and the mononuclear
cells are retained at the interface. Percoll (polyvinyl
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pyrrolidone-coated silica in water) has also been used to isolate
mononuclear cells. Nordlind (1984) stated that greater significant
differences between nickel-sensitive patients and controls were
obtained in a nickel sulphate LTT using Percoll instead of Ficoll-
Paque. However, both patient and control cells were stimulated by
the nickel sulphate at the concentrations studied. Prior to the
use of Ficoll-Paque, separation methods may have damaged the
leucocytes; cells were viable before culture, but after a 6-day
culture, viability decreased to 44-53% (Hughes and Caspary, 1970).
Constituents of Tissue Culture Medium
Constituents of the medium (TCM) used in the LTT have been
maintained during the development of the assay. However, the serum
or plasma source (autologous or human AB serum) to be used remains
a controversial issue. Autologous serum may contain antibodies
capable of neutralising antigen, thus decreasing antigen
availability for lymphocyte stimulation (Pentycross, 1968). In
addition, certain substances (eg steroids) which inhibit lymphocyte
stimulation (Casey and McCall, 1971) may be present in the serum of
certain individuals, indicating that pooled human AB serum may be
more suitable for use. However, factors in autologous serum may
mimic the _iii vivo situation more accurately. Furthermore, the use
of autologous plasma in the LTT may provide better discrimination
between sensitised patients and negative controls (Hicks ejt al.,
1986). Therefore, autologous plasma was used in the assay system
described in this thesis.
Measurement of Transformation
Lymphocyte transformation was initially quantified by the
morphological assessment of blast cells in prepared smears. The
percentage of cells scored as transformed depends on a number of
variables, including the technique used for film preparation, the
counting procedure and the definition of a transformed cell.
Furthermore, substances initiating cell clumping (eg PHA) make many
cells morphologically unrecognisable (Pentycross, 1968). Reliable
results are obtained only by counting at least 4000 cells. After
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cell transformation different cell morphologies exist including:-
(1) cells with obvious mitotic figures
(2) large (20-40pm) transformed cells with stippled nuclear
chromatin, visible nucleoli and abundant basophilic cytoplasm
(3) small and medium lymphocytes
(4) dead cells
Approximately 90% of the cells belong to categories 2 and 3
(Pentycross, 1968).
It should be remembered that whilst the first morphological
studies were being performed, little was known about the role of
lymphocytes in the immune response. In 1962, Carstairs suggested
that the blast cells may have originated from one of three sources-
contaminating multipotential cells, medium and large lymphocytes,
and the small lymphocytes (the source supported by his data).
Lymphocyte transformation studies employing a second technique
(autoradiography) with tritiated thymidine and colchicine showed
that the mitotic figures in PHA-enriched leucocytes present after
culture were transformed lymphocytes and did not arise from cells
in DNA synthesis at time zero, or from other small populations of
cells (Mackinney e_t , 1962). The authors concluded "...that the
sequence of morphological patterns of mononuclear cells represented
developmental stages or transformation of the small lymphocytes."
The technique now commonly used to study lymphocyte
transformation is the estimation of radioactive thymidine uptake
into cells by liquid scintillation counting (Caron et_ al_., 1965).
This technique provides a quantitative method of assessing lympho¬
cyte transformation _in vitro without requiring identification of
particular cells. Initially, dissolution of the cells in hyamine
was required; later, a less time-consuming millipore filtration
technique was developed (Robbins e_t _al_., 1972). The advent of
microculture in the mid 1970s and the use of automatic cell
harvesters have increased the efficiency, rapidity and sensitivity
of the assay.
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The Lymphocyte Transformation Test In The Diagnosis Of Nickel
Allergy
The LTT has become a valuable research technique and has been
used widely to study the role of lymphocytes in nickel
hypersensitivity.
Nature of Antigen Recognised
Three different nickel salts have been used in the LTT; nickel
acetate, nickel chloride and nickel sulphate. However, the actual
antigen which induces specific lymphocyte transformation is
unknown. Nickel may conjugate with amino acids or proteins in
serum, bind directly to lymphocytes or react with serum components
to produce a sensitiser (Hutchinson et^ al., 1975). Using
C■ O
radioactive nickel Ni, Hutchinson £t_ al. (1975) showed that
lysine was a major binding amino acid and that nickel also binds to
approximately 20% of lymphocytes from both nickel-sensitive
individuals and controls. Nickel-binding proteins in serum and
peripheral blood mononuclear cells are not different in nickel-
sensitive patients and controls (Silvennoinen-Kassinen e_t al.,
1987). Veien _et al. (1980) investigated nickel binding to cells
and showed that 90-99% of the nickel could be removed in three
thirty minute washes. However, nickel remaining on the pulsed
cells could still initiate lymphocyte transformation. The authors
also suggested that albumin-nickel (described by Lucassen and
Sarkar, 1979) was not bound to the lymphocytes. Direct binding to
lymphocyte membranes was postulated by Nordlind and Henze (1984)
when they studied the effects of nickel sulphate on thymocytes in
the presence or absence of serum. Earlier investigators had
concluded "One can do no more than speculate on the nature of the
antigen in our _rn vitro experiments for the medium, consisting of
plasma, medium 199, and disintegrating cells, offers a multitude of
amino acid complexes, peptides, and proteins, to the nickel
hapten." (Macleod et al., 1970).
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The first investigators of nickel-specific lymphocyte
transformation used morphological criteria to establish specific
stimulation by nickel acetate and described transformation in cells
from both nickel-sensitive individuals and controls (Aspegren and
Rorsman, 1962). These observations were supported by Pappas et al.
(1970) who incubated nickel acetate (10-30pg/ml) with cells from
eight controls and three nickel-sensitive individuals, and carried
out morphological and autoradiographic studies. The same response
was evident in all eleven cultures.
Using liquid scintillation counting and the antigen nickel
chloride (at concentrations of 2.5-30jug/ml), Millikan ^t_ a_l. (1973)
described nickel-specific lymphocyte transformation (in contrast to
a non-specific mitogenic response). However, the antigen used in
LTTs to detect nickel sensitivity is commonly nickel sulphate.
Variable results obtained from some previous LTTs using nickel
sulphate to detect nickel sensitivity are shown in Table 1.6.
In the first study carried out by Macleod e_t a_l. (1970), only
one nickel sulphate concentration (14jag/ml) was studied and 7/12 of
the nickel-sensitive patients were positive in the LTT. Cells from
the controls were not stimulated, suggesting that 14pg/ml nickel
sulphate was not mitogenic. Forman and Alexander (1972) also
claimed that the LTT using nickel sulphate (concentrations not
stated) would provide a useful _in_ vitro test for detecting nickel-
sensitive individuals.
Gimenez-Camarasa et al. (1975) used serial dilutions of nickel
sulphate in the LTT to detect nickel sensitivity and described two
types of specific response. Fourteen patients had maximum
thymidine incorporation at the lowest nickel sulphate concentration
(O.lpg/ml); conversely, eleven patients showed maximum thymidine
incorporation at the highest salt concentration (lOpg/ml).
















































































significantly in the LTT and they suggested that nickel sulphate
may be mitogenic or that the LTT is more sensitive than patch
testing to identify nickel-sensitive individuals.
It is therefore necessary for investigators using the LTT to
define carefully parameters of the assay which distinguish nickel-
sensitive patients from negative controls. In 1981, Al-Tawil e_t
al. outlined criteria related to stimulation indices of patients
and controls on days 5 and 6 of culture using 6.25-25 pg/ml nickel
sulphate. Although they were successful in detecting 15/16
patients, the criteria they employed were complicated (requiring
two different stimulation indices, three different nickel sulphate
concentrations and comparing the results with non-sensitised
controls). Therefore, the description of an assay system which can
discriminate easily between nickel-sensitive patients and controls
would be valuable and would remove the necessity for patch testing.
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OUTLINE OF THE INVESTIGATION
The overall aim of the work described in this thesis was to
use and adapt the LTT to investigate the _iri vitro presentation of
nickel sulphate to cells obtained from nickel-sensitive patients
and negative controls. Two aspects of nickel presentation were
studied:-
(1) The abilities of blood and epidermal cells to present
nickel to enriched T-cells (Chapter 4).
(2) The role of MHC II antigens (HLA-DP -DQ -DR) in nickel-
specific T-cell proliferation (Chapter 5).
However, it was first necessary to establish a LTT which could





Patch testing equipment is shown in fig 2.1. Commercially
prepared allergen (Trolab, Denmark) was placed in an aluminium Finn
chamber (Pirila, 1975) and applied to the patient's upper back,
using Scanpor (Epitest Ltd, Finland) avoiding the skin over the
vertebral column (fig 2.2). This site produces the strongest
allergic and irritant reactions (Magnusson and Hersle, 1965). The
Finn chamber's design (diameter 8mm, depth 0.5mm) promotes good
occlusion, localises reactions to the test sites and permits the
use of porous tape for patch test application.
Test sites were marked with pen on the patient's back and the
chambers removed after 48 hours. Patients were instructed to
protect the test sites from water and to avoid scratching reacting
sites. Sites were examined half an hour after patch test removal,
allowing time for a positive reaction to become evident. Patients
returned for a second reading at 120 hours when most allergic
reactions would be present, but irritant reactions would have
subsided.
Patch test results were scored using a recognised recording
system recommended by the ICDRG (Fregert and Bandmann, 1975):
Table 2.1 Scoring of Patch Test Results
Negative
+? Doubtful reaction; faint erythema
+ Weak; palpable erythema, infiltration, possibly papules.
++ Strong; erythema, infiltration, papules, vesicles
+++ Extreme; intense erythema and infiltration, coalescing
vesicles
Patch test reactions are shown in figs 2.3 and 2.4.
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Fig 2.1 Patch Testing Equipment
Commercially prepared antigen (in the syringe) is placed in the
aluminium chambers.
Fig 2.2
The chambers are then applied to the patient's upper back.
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Patch Test Reactions




Patients in this study are defined as those subjects with
positive patch tests to 5% nickel sulphate when tested with the
European Standard Battery of contact allergens (Table 1.3, page
22). Blood samples were obtained from most patients when they
attended the patch test clinic for the 120hr reading.
Peripheral blood mononuclear cells from two patients, Pa and
Pb (nickel patch test reactions +++(48hr) ++(120hr) and ++(48hr)
++(120hr) respectively) were used to establish the toxicity of
nickel sulphate in a 5 day LTT.
A review of patients studied in the 6 and 7 day LTTs with the
results of patch testing and clinical manifestations is shown in
Table 2.2.
Key For Tables 2.2 and 2.3
Cr = Chromium Form = Formaldehyde
BoP = Balsam of Peru Frag = Fragrance mix
Co = Cobalt Col = Colophony
Neo = Neomycin Prim = Primin
Cai = Caine mix W.T. = Wool Tars
N.A. = Not Available N.T. = Not Tested
(but known to be positive)
Controls
Controls in this study were mostly healthy volunteers who had
no history of metal contact dermatitis (C7-C46); however, some
controls were patients attending the patch test clinic with
histories suggesting nickel sensitivity but who did not react to
the nickel sulphate patch test (C1-C6). Information about the
controls is shown in Table 2.3.
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Table 2.2 Details of Patients Studied
No■ Sex Age P.T.
(M/F) Date
Nickel P.T. Other P.T. Clinical Manifestations
Reactions Reactions And Other Information
48hr 120hr 48hr 120hr
PI F 45 1/86 ++ ++ Jewellery reaction
P2 F 60 1/82 + + +++ Hand dermatitis
P3 F 35 3/86 + + + +++ Co - + Jewellery reaction
P4 F 30 5/85 + + ++ Co + +
P5 F 47 8/82 ++ + +++ Hand dermatitis
P6 F 66 4/86 ++ ++ BoP + + Jewellery reaction
P7 F 30 7/86 ++ ++ Cr + + Hand and wrist eczema
Frag + +
P8 F 61 5/86 - + Co - + Reacts to watch
P9 F 26 ++ ++ Co - + Hand dermatitis
P10 F 28 8/86 + ? + Form + ? + Atopic eczema
Pll F 19 8/86 ++ +++ Co + + Blisters on palms
P12 F 26 8/86 + + Co + + ++ Microvesicular on palms
Cr - + +
P13 F 22 9/86 + ++ Co + Probably atopic
P14 M 59 6/83 +++ ++ Co ++ ++ Pompholyx
Cai + ++ ++
W.T. ++ +
PI 5 F 32 10/86 N.A. N.A. Hand dermatitis
P16 F 56 10/86 ++ ++ Chronic palmar eczema
PI 7 F 56 10/86 ++ ++
P18 F 33 11/84 ++ ++ Co + + Jewellery reaction
Frag + +
P19 F 26 11/86 ++ ++ Co + + Recurrent eczema
P20 M 22 11/86 ++ ++ Wrists vesicular
P21 F 36 4/86 + + Co - + Atopic. Wet work
Frag + +
P22 F 22 12/86 ++ ++ Co ++ ++ Constitutional eczema
Frag ++ ++
P23 F 61 12/86 + ++ Hand dermatitis
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Table 2.2contd
No. Sex Age P.T.
(M/F) Date
Nickel P.T. Other P.T. Clinical Manifestations
Reactions Reactions And Other Information
48hr 120hr 48hr 120hr
P24 F 38 1/87 - ++ Foot dermatitis
P25 F 22 1/87 ++ ++ Form + + Jewellery reaction
Col + +
P26 F 16 1/87 ++ ++ Col - + Earring reaction
P27 F 26 2/87 +++ +++ Jewellery reaction
P28 M 22 2/87 ++ ++ Dyes + + Mild hand dermatitis
P29 F 25 7/83 +++ +++ Form - + Blisters within minutes
of contact. Angry back
P30 F 70 2/87 + ++ Cr - + Hyperkeratotic
Co ++ ++ dermatitis
Frag + ++ Slight earring reaction
Prim - ++
P31 F 24 2/87 + ? ++ Co - +
P32 M 43 2/87 + ? + Cr ++ + + + Foot eczema
Co + ++
Form + +
P33 F 22 3/87 + ? + Hand eczema. Asthma
P34 F 42 2/87 - + Erythrodermic
dermatitis
P35 F 16 4/87 + + Atopic eczema. Hand
eczema
P36 F 17 3/87 - + Hand dermatitis
P37 F 23 3/87 ++ ++ Co + +
Form + + ++
Para + ++
P38 F + ++
P39 F 30 4/83 ++ ++ Constitutional
pompholyx
P40 M 38 1/87 ++ ++ Cr ++ ++ Cement worker
Co + +
P41 F 56 2/86 +++ +++ Jewellery reaction
P42 F 45 4/87 + ++ Works with metal pins
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Table 2.2 contd
No. Sex Age P.T. Nickel P.T., Other P .T. Clinical Manifestatioi
(M/F) Date Reactions Reactions And Other Information
48hr 120hr 48hr 120hr
P43 F 18 4/87 + ++ Form + ++ Atopic eczema
P44 M 46 4/87 + ++ Microvesicular palms
P45 F 20 3/87 + ++ Form ++ + +++ Earring reaction
P46 F 19 6/87 + ++ Neo + ++ Earring reaction
P47 F 16 6/87 +++ ++ Hand dermatitis
P48 M 56 5/87 +++ +++ Wrist watch reaction
P49 F 33 6/87 N. A. ++
P50 F 26 6/87 + ++ Cr - + ? Jewellery reaction
P51 F 63 7/84 +++ +++ Co + + ++ Jewellery reaction
Frag ++ + + Works with metal card:
Neo - ++
P52 F 18 6/87 +++ +++ Vesicular hand eczema
P53 F 75 7/87 + ++ Jewellery reaction
P54 F 17 7/87 ++ ++
P55 M 29 8/87 + ++ Cr + + Hand dermatitis
Col + +
P56 F 27 8/87 + ? + Form + + ++ Cheiropompholyx
P57 F 17 8/87
P58 F 20 8/87 + + Cr + +
Co + ? +
P59 F 32 8/87 - + Mild eczema
P60 F 19 8/87 + + Jewellery reaction
P61 F 18 8/87 N. A. N.A.
P62 F 21 8/87 + ++ Co + ++ Earring reaction
P63 F 17 10/87 ++ ++ Col +++ +++ Jewellery reaction
Frag ++ ++
Form + + ++
BoP + +
P64 F 32 10/87 + + Frag ++ ++ Wrist dermatitis
Col - ++
P65 F 18 11/87 + + Not 1tested
P66 F 40 11/87 +++ +++ Jewellery reaction
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Table 2.3 Details of Controls Studied
(a) Patch Test Negative Patients
No. Sex AgeP.T. Nickel P.T. Other P.T. Clinical Manifestations
(M/F) Date Reactions Reactions And Other Information
48hr 120hr 48hr 120hr
CI F 34 1/87 Hand eczema. Atopic
eczema previously
C2 F 43 2/87 " - Col - + Hairdresser. Eczema
fingertips
C3 F 47 1/87 - +? Prim + + Irritant eczema
C4 F 27 3/87 - -
C5 M 39 3/87 - - Probably psoriasis
C6 F 17 3/87 - -
Controls With No History of Metal Contact Dermatitis
No. Sex Age No. Sex Age No. Sex Age
(M/F) (M/F) (M/F)
C7 F 23 C21 M 31 C34 F 50
C8 F 50 C22 F 38 C35 F 45
C9 F 35 C23 M 33 C36 F 23
CIO F 24 C24 F 25 C37 F 54
Cll F 54 C25 M 30 C38 F 51
C12 F 29 C26 M 20 C39 F 25
C13 F 23 C27 M 32 C40 F 22
C14 M 34 C28 F 22 C41 F 35
CI 5 F 24 C29 F 54 C42 F 49
C16 F 34 C30 M 30 C43 F 34
C17 F 29 C31 M 49 C44 F 51
C18 F 43 C32 M 31 C45 F 30









0.08% sodium bicarbonate (above purchased from Gibco, Paisley)
2xlO~^M 2-mercaptoethanol (Sigma, Poole)




Potassium dihydrogen orthophosphate 0.2g






NAMES AND ADDRESSES OF SUPPLIERS
Materials used during the experiments are listed with the
names and addresses of the suppliers in Appendix II (pages 175-77).
PREPARATION OF CELL POPULATIONS
Preparation of Peripheral Blood Mononuclear Cells
Blood (30-60ml) was obtained by venepuncture and placed in
heparinised tubes (10IU heparin/ml, Sigma, Poole). Five ml blood
was layered onto an equal volume of lymphocyte separation medium
(Flow, Rickmansworth) in 10ml conical tubes and centrifuged
(400g, 20 mins, room temperature). The plasma was collected, then
the mononuclear cells (PBM) were harvested from the interface and
washed three times in phosphate buffered saline (PBS).
Antigen Presenting Cells
The abilities of
(a) plastic-adherent blood cells and
(b) epidermal cells
to present Con A and NiSO^ to enriched T-cells in the LTT were
studied.
In these experiments, plasma was filtered to remove any
contaminating cells and then added to TCM at a concentration of
15%. Once obtained, PBM and antigen presenting cells were
maintained at 4°C to prevent cell adherence.
(a) Plastic-Adherent Blood Cells
PBM were resuspended in TCM+15% autologous plasma, and
incubated in plastic petri dishes at 37°C for 45 minutes. The non¬
adherent cells were removed by washing the dishes with PBS. The
plastic-adherent cells were removed from the dishes by gentle
scraping with a 1ml syringe plunger. The cells were washed,
resuspended in TCM+15% autologous plasma and irradiated with 3000
I 0"7
rads using Cs (RX2/50 irradiator (Gravatom Industries Ltd)).
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(b) Epidermal Cells
A method to obtain epidermal cells from suction blisters was
originally described by Kistaala (1968). This method was adapted
to obtain epidermal cells from patients and controls. Sterile
suction devices with five holes of 5mm diameter were placed on the
volar aspects of the upper arms and held in position by tape. A
vacuum (-300mm Hg) was then applied to the devices for
approximately \\ hours until five blisters had been raised and were
easily visible through the cups (fig 2.5). Blister roofs (fig 2.6)
were removed aseptically and placed in PBS containing 500IU/ml
penicillin, 500jug/ml streptomycin, 250jjg/ml gentamycin and
12.5jug/ml fungizone for 45 minutes. Blister roofs were then
incubated for 45 minutes with 0.3% trypsin at 37°C. The roofs were
gently agitated to release epidermal cells and washed three times
in TCM+5% foetal calf serum (FCS) to inactivate the trypsin. The
stratum corneum was not pelleted and was easily removed with the
washing solution. Cells were resuspended in TCM+15% autologous
plasma and irradiated (3000 rads).
T-cell Enrichment
Enriched T-cells were prepared from the plastic-non-adherent
blood cells by either
(a) T-cell rosetting or
(b) nylon wool passage
(a) T-Cell Rosetting
(1) Sheep Red Blood Cells (SRBC)
SRBC in 50% Alsever's solution (Moredun Research Institute,
Edinburgh) were washed twice in PBS.
(2) AET-SRBC
One volume of packed SRBC was incubated with 4 volumes of
aminoethylisothiuronium bromide hydrobromide (AET, Sigma, Poole)
(4%w/v in saline, pH 9.0) for 15 minutes at 37°C. Cells were
washed three times and resuspended at 2%v/v in TCM + 20% FCS.
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Equal volumes of 2% AET-SRBC
FCS
and plastic-non-adherent blood cells (3-4xl0^/ml)
were mixed and pelleted (150g, 5mins, 4°C)in a 20ml conical tube.
Cells were incubated on ice for 90 minutes then the supernatant was
removed. Rosettes were gently resuspended in TCM+30% FCS and
clumps (which may contain non-rosetted cells) were allowed to
settle at the bottom of the tube. The rosettes were layered onto
lymphocyte separation medium (4°C) and centrifuged (400g, 20mins,
4°C). Cells at the interface were harvested, washed and
resuspended in 0.5ml TCM+15% autologous plasma. The cells were
mixed to dissociate the rosettes, then resuspended in 1ml lysis
medium (lvol TCM + 5 vols distilled water) to remove the SRBC.
Cells were mixed vigorously for 2 seconds, then 20ml TCM was added.
Cells were washed in PBS, then resuspended in TCM+15% autologous
plasma.
(b) Nylon Wool Passage
(1) Preparation of Nylon Wool Column
One g nylon wool (Fenwall, Illinois, USA) was packed into a
5ml syringe and sterilised. Columns were incubated at 37°C with
TCM+5% FCS for 1 hour before the addition of plastic-non-adherent
cells.
(2) T-Cell Enrichment (fig 2.7)
Plastic-non-adherent blood cells were resuspended in
approximately 0.7ml TCM+5% autologous plasma and incubated in the
column for 1 hour at 37°C. The cells were then washed from the
column under the force of gravity using TCM+5% autologous plasma.
Nylon wool-non-adherent cells were further incubated on glass for
2\ hours at 37°C in TCM+15% autologous plasma. The glass-non-
adherent cells were an enriched population of T-cells.
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Fig 2.7 Summary of Method used for T-Cell Enrichment
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Characterisation of Cell Populations
Whenever possible, the PBM, plastic-adherent blood cells, T-
cells and epidermal cells were characterised by
a) The expression of HLA-DP-DQ-DR (using indirect immuno¬
fluorescence)
b) Staining of dendritic cells
Specific staining of dendritic cells using the monoclonal
antibody RFDl (Poulter £t _al. , 1984) was unsuccessful at dilutions
ranging between 1/5 and 1/100. The low numbers of dendritic cells
in PBM made it impossible to ascertain the percentage of these
cells present in the accessory cell population using two antibodies
DA6.231 and Leu M3 (an antibody against monocytes/macrophages,
Becton Dickinson, Teddington) (3% difference found).
Indirect Immunofluorescence
Cells (2x10^) were incubated with 20% normal rabbit serum
(NRS) in PBS for 10 minutes and then washed. Monoclonal antibody
DA6.231 (anti HLA-DP-DQ-DR; Guy e_t al_. , 1982) was added at a
dilution of 1/40 in 20% NRS for 40 minutes at 4°C. Cells were
washed three times in PBS, then 1/40 fluorescein conjugate (FITC-
rabbit anti-mouse immunoglobulin (Fab fragment), Cappel,
Philadelphia, USA)) was added for a further 40 minutes (4°C).
Cells were washed three times, mounted in glycerol and studied




Concanavalin A (Con A; Sigma, Poole) was used at a final
concentration of lOpg/ml.
Nickel Sulphate (NiSO^.y^O, Analar, BDH, Glasgow). A l%w/v
NiSO^.y^O stock solution was prepared in physiological saline,
filter sterilised and stored at 4°C. When required, the stock
solution was diluted 1/20 in RPMI 1640 and added to the cells at
final concentrations varying between 0 and 50jig/ml.
Peripheral Blood Mononuclear Cells (PBM) (fig 2.8)
Mononuclear cells were resuspended in tissue culture medium
(TCM) containing 15% autologous plasma. An aliquot of cell
suspension was diluted in trypan blue (Flow, Rickmansworth, final
concentration 0.05%) to determine cell viability. Cells were
counted using a Neubauer haemocytometer; viable cells, which
exclude trypan blue, were expressed as a percentage of the total
number of cells present.
PBM were diluted to a concentration of 10^/ml in TCM+15%
autologous plasma, then aliquoted into sterile 5ml culture tubes
(Elkay, Basingstoke). Stimulant was added to the tubes and the
solutions mixed. Aliquots (200]ul) were placed in individual wells
of a Linbro tissue culture plate. Cells (2xl0^/well) were then
incubated for 6 or 7 days in a humidified Vindon incubator with 5%
co2-
3
Lymphocyte transformation was measured by incorporation of H-
thymidine (Amersham); lpCi of radiolabel was added to each well,
18-20 hours before harvesting cells onto filter discs (Skatron,
Northumbria Biologicals, Cramlington) using a Dynatech automatic
MASH II cell harvester. Filter discs were then placed in
scintillation vials with 3ml scintillation fluid (2.51 toluene,
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12.5g 2,5-diphenyloxazole (PPO), 0.5g 1,4-di(2-methylstyryl)-
benzene (Bis-MSB)); their radioactivity was determined using a
Packard Tricarb 300 liquid scintillation counter.
Results obtained were expressed as a stimulation index (SI).
SI = cells + stimulant (cpm)
cells alone (cpm)
Stimulation indices greater than or equal to 3 were considered
to be a positive response in the test (see results section).
Antigen Presentation By Plastic-Adherent Cells and Epidermal Cells
The LTT was carried out using the cell concentrations shown
in Table 2.4.:-





T + Adherent cells





106 + 105 10
106 + 105-4x105 10-40
Stimulant was added to the cells, the solutions mixed and 200jil
aliquoted into individual wells. Plates were incubated for 6 days
at 37°C with 5% CO2 before cell harvesting.
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Inhibition of LTT by Monoclonal Antibodies Against MHC II Molecules
The monoclonal antibodies studied in these experiments are
shown in Table 2.5.
Table 2.5 Description of Monoclonal Antibodies Studied
Monoclonal supernate/ Class Supplier Class II MHC
Antibody ascites recognised
DA6.231 ascites IgGl K. Guy HLA-DP-DQ-DR
L243 supernate IgG2a S. Howie HLA-DR
B7/21 ascites IgGl Becton Dickinson HLA-DP
Leu-10 ascites IgGl Becton Dickinson HLA-DQ
L368 ascites IgGl Becton Dickinson Beta2 micro-
globulin
Becton Dickinson antibodies were dialysed against PBS for 48
hours to remove sodium azide preservative and then sterile
filtered. Concentrations of the five antibodies studied were
determined by ELISA (see page 63).
(1) Destruction of MHC II"1" Cells Using Antibody and Complement
PBM were incubated for 30 minutes at room temperature firstly
with DA6.231 (1/5000 dilution), followed by rabbit anti mouse serum
(1/100 dilution) and washed three times with PBS. The cells were
warmed to 37°C and then guinea pig complement (Bacteriology
Department, University of Edinburgh) (previously absorbed with SRBC
and human PBM) was added (1/20 dilution). Cells were incubated
with complement for 45 minutes at 37°C, then washed three times
with PBS. Cells were resuspended at 10^/ml in TCM+15% autologous
plasma. Stimulant was added, the cells were placed in tissue
culture plates and the LTT was carried out.
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(2) Pulsing with Antibodies
After incubation with antibody for 1 hour at room temperature,
10^ PBM were washed with PBS and resuspended in 1ml of TCM+15%
autologous plasma. Stimulants were added to the cells and 200pl
placed in the wells of a tissue culture plate. The LTT was then
carried out.
(3) Maintaining Antibody in the Culture
Stimulants were added to PBM after they had been incubated
with the antibodies for 1 hour at room temperature. The cells were
then placed in tissue culture plates and the LTT carried out. In
reconstitution experiments, antibody was incubated with the
plastic-adherent blood cells for 1 hour before the addition of T-
cells and stimulants.
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ELISA TO DETERMINE MONOCLONAL ANTIBODY CONCENTRATIONS
Washings were carried out three times using PBS + 0.05% Tween
(1) Plate Coating
Anti mouse IgG (61pg/ml) (Sigma, Poole) was prepared in PBS in
a glass container, and lOOpl were added to the wells of an ELISA




Mouse IgG (Sigma) was prepared at concentrations between 0-
2000ng/ml in TCM+5% FCS.
Monoclonal antibodies were diluted in TCM+5% FCS.
One hundred microlitres were added to triplicate wells and plates
were incubated at room temperature for 90 minutes, then washed.
(3) Conjugate
Anti mouse IgG-alkaline phosphatase conjugate (Sigma) was
diluted 1/400 in PBS and centrifuged (3000rpm, 20 mins) and lOOpl
were added to each well. Plates were incubated overnight at 4°C,
then washed.
(4) Substrate
Para-nitrophenyl phosphate (lmg/ml) (Sigma) was prepared in
substrate buffer (pH 10.4, see page 51). Colour was allowed to
develop for 15 minutes at room temperature. The reaction was
stopped by the addition of 25pl 3M sodium hydroxide. Plates were
read using a Titertek MR580 Microelisa autoreader at 405nm.
- 63 -
RESULTS
DEVELOPMENT OF THE LYMPHOCYTE TRANSFORMATION TEST
Before using the LTT to detect nickel sensitivity, it was
necessary to establish optimal antigen concentrations and
incubation periods for the assay. The method is described in
detail on pages 58-60.
(1) Toxicity of Nickel Sulphate
Cells were incubated for 5 days with concentrations of nickel
sulphate ranging from 0-50pg/ml in the presence of the mitogen Con
A at a concentration of lOjig/ml.
Figure 3.1 shows the percentage inhibition of the response of
cells to Con A by co-culture with increasing concentrations of
nickel sulphate. Responses to Con A were similar in cells from
patch test positive patients and controls. The Con A response was
markedly inhibited at nickel sulphate concentrations greater than
30pg/ml (50-80% inhibition). Therefore, these concentrations of
antigen were considered to be toxic. The effect of lower nickel
sulphate concentrations was variable; some cells were inhibited,
other cells were stimulated.
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Fig3.1
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(2) Time Course Studies and Dose Responses
Having established that nickel sulphate concentrations greater
than 30pg/ml should not be used because of toxicity, time course
and dose response studies were carried out to establish the optimal
culture times and nickel sulphate concentrations to be used in
further experiments. Initial experiments were carried out using 0-
20jug/ml of nickel sulphate in 5-8 day assays.
Results from two experiments are shown in figs 3.2-3.5 and
can be summarised as follows:-
Day 5 (fig 3.2):- Cells from nickel-sensitive patients
exhibited a dose dependent response to nickel sulphate. There was
no response from the controls' cells at concentrations of O-lCtyig/ml
of nickel sulphate; however, for one individual (C7, fig 3.2c),
20pg/ml was weakly mitogenic.
Day 6 (fig 3.3):- The response of the nickel-sensitive
patients' cells increased. One control (C7) responded to 10 and
20pg/ml of nickel sulphate (fig 3.3c)
Day 7 (fig 3.4):- Nickel-sensitive patient lymphocytes were at
maximum stimulation; however, the background values were increased
(thus decreasing stimulation indices).
Day 8 (fig 3.5):- Lymphocyte transformation at higher nickel
sulphate concentrations decreased.
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PBM from 2 nickel-sensitive patients and 2 non-sensitised controls
were incubated with 0-20jug/ml of NiSO^ in a 5 day LTT. Results in
cpm x 10" (mean + SD)
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Fig 3.3a Fig 3.3b
Dose Response Curve : Day 6
Patient 1
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PBM from 2 nickel-sensitive patients and 2 non-sensitised controls
were incubated with 0-20jng/ml NiSO^ in a 6 day LTT. Results in cpm
x 10-^ (mean + SD).
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Fig 3.4a Fig 3.4b
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PBM from 2 nickel-sensitive patients and 2 non-sensitised controls
were incubated with 0-20pg/ml NiSO^ in a 7 day LTT.
Results in cpm x 10 ^ (mean + SD)
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Fig 3.5a Fig 3.5b
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PBM from 2 nickel-sensitive patients and 2 non-sensitised controls
were incubated with 0-20pg/ml NiSO^ in an 8 day LTT. Results in
cpm x 10 3 (mean + SD)
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Time course curves for nickel sulphate concentrations of 2.5-
20pg/ml are shown in fig 3.6. Stimulation indices are plotted,
thus accounting for increasing background values. (The increased
SI on day 8 (P6) resulted from a decreased background level).
These initial experiments indicated that stimulation indices were
maximal in 6 day assays. The stimulation index for control C7 was
greater than 3 on day 6 when cells were incubated with 20pg/ml of
nickel sulphate (fig 3.6a) and the SI was 2.5 with 10)Ug/ml (fig
3.6b). Therefore, 5jug/ml of nickel sulphate (SI approximately 1
for control cells) was chosen as a suitable concentration to




PBM were incubated with 0-20]ug/ml NiSO^ in 5, 6, 7 and 8 day
LTTs. The SI (cells with NiSO^ (cpm))/(cells in medium (cpm)) were
calculated and plotted for each antigen concentration against
culture time (days) (figs 3.6a-d).
Fig3.6a
TimeCourseurvesf rNick lS lphate 20jjg/ml StimulationIndex 30
to
-Patienti -Patient6 -Control7 -Control10
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TimeCourseurvesf rNick lS lphate 5pg/ml StimulationIndex 30
Fig3.6c
DaysinCulture
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Patient1 Patient6 Control7 Control10
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THE EFFECTS OF PATCH TESTING ON THE LTT
A blood sample was taken from the majority of the nickel-
sensitive patients when they attended the patch test clinic for
their day 5 reading (ie 72 hours after patch removal). To ensure
that patch testing was not influencing the outcome of the LTT, a
blood sample was taken from six patients (P25, P33, P37, P47, P55
and P61) immediately before patch test application and when they
attended the clinic for the day 5 reading. The stimulation indices
are shown in fig 3.7; results obtained pre- and post-patch testing










I V» i3 '—1 — '
Pre PT (Day 0) Post PT (Day 5)
Two blood samples were taken from 6 patients when they attended the
patch test clinic. The first was obtained before patch test
application (day 0) and the second taken when they returned to the
clinic for the day 5 reading. SI obtained using the two blood
samples in the 6 day LTT were compared and were not significantly
different (p>0.05; Wilcoxon's Rank Sum Test)
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THE DETECTION OF NICKEL SENSITIVITY USING THE LTT
The 6 day LTT has been used to obtain dose response curves
for PBM from 66 nickel-sensitive patients (58 females, 8 males,
mean age=33) and 46 controls (32 females, 14 males, mean age=35).
Peripheral blood mononuclear cells from 56 of the patients and 43
of the controls have also been studied in the 7 day LTT. Results
are shown in Appendices III and IV (pages 178-86); representative
results from 4 patients and 4 controls are shown in figs 3.8 and
3.9.
A stimulation index greater than or equal to 3 using 5pg/ml of
nickel sulphate was chosen to discriminate between nickel-sensitive
patients and controls (see page 71). Stimulation indices obtained
from patients' cells using this antigen concentration are shown
together with patch test results in Table 3.1; stimulation indices
from control cells incubated with 5pg/ml of nickel sulphate are




NickelSulphateDosResponsCurv s 6DayAssay cpmx1/1000 80 5105 NickelSulphate(pg/m )
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Fig3.9
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Table 3.1 Patient Stimulation Indices Obtained With 5pg/ml NiSO^
And Patch Test Results
Pat Nickel P.T. SI Pat Nickel P.T. SI
Reaction Day 6 Day 7 Reaction Day 6 Day 7
PI ++ ++ 18.0 7.0 P2 ++ +++ 14.6 N.T.
P3 +++ + + + 23.0 N.T P4 ++ ++ 29.0 6.1
P5 +++ +++ 7.3 N.T P6 ++ ++ 11.0 9.8
P7 ++ ++ 6.4 20.2 P8 - + 9.0 71.0
P9 ++ ++ 12.9 5.5 P10 + ? + 7.3 15.9
Pll ++ +++ 79.0 N.T. P12 + + 3.9 N.T.
P13 + ++ 18.8 28.9 P14 +++ ++ 22.0 N.T.
PI 5 N. A. N.A. 7.1 N.T P16 ++ ++ 2.1 4.7
P17 ++ ++ 3.6 7.9 P18 + + ++ 5.6 N.T.
P19 ++ ++ 3.1 10.7 P20 ++ ++ 7.3 15.4
P21 + + 3.3 5.8 P22 ++ ++ 3.5 5.6
P23 + + + 19.2 14.1 P24 - + + 1.9 3.2
P25 ++ ++ 6.3 16.4 P26 + + ++ 6.3 2.5
P27 ++ + + + + 28.2 29.0 P28 ++ + + 19.6 15.2
P29 +++ +++ 15.9 13.0 P30 + ++ 2.9 4.3
P31 + ? ++ 3.0 3.5 P32 + ? + 2.4 4.2
P33 + ? + 3.4 3.2 P34 - + 5.4 3.2
P35 + + 3.0 3.6 P36 - + 3.6 3.0
P37 + + ++ 4.5 4.9 P38 + ++ 3.1 4.8
P39 ++ ++ 3.7 5.6 P40 ++ ++ 5.5 N.T.
P41 ++ + +++ 3.2 N.T. P42 + ++ 3.3 5.4
P43 + ++ 4.4 10.0 P44 + ++ 4.6 4.3
P45 + ++ 3.6 4.8 P46 + ++ 6.3 2.5
P47 +++ ++ 4.4 6.4 P48 +++ +++ 6.5 N.T.
P49 N.A. ++ 2.4 3.0 P50 + ++ 4.1 3.4
P51 ++ + +++ 12.6 13.8 P52 ++ + +++ 2.1 1.9
P53 + ++ 2.1 2.9 P54 ++ ++ 12.0 11.9
P55 + ++ 5.3 3.3 P56 + ? + 2.3 2.7
P57 N.A. N.A. 2.5 5.3 P58 + + 2.7 2.1
P59 - + 4.5 3.3 P60 + + 3.3 3.5
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Table 3.1 contd
Pat Nickel P.T. SI
Reaction Day 6 Day 7
Pat Nickel P.T. SI
Reaction Day 6 Day 7
P61 N.A. N.A. 7.3 4.4 P62 + ++ 3.4 9.7
P63 ++ ++ 5.0 3.4 P64 + + 1.8 1.4
P65 + + 4.5 7.8 P66 +++ +++ 21.2 11.6
N. A. = Not Available N.T.= Not Tested
(but known to be positive)
"able 3.2 Control Stimulation Indices Obtained Using 5pg/ml
Cont SI Cont SI Cont SI
Day 6 Day 7 Day 6 Day 7 Day 6 Day 7
CI 1.0 0.5 C2 0.7 0.8 C3 2.0 2.4
C4 1.5 1.5 C5 0.7 0.6 C6 0.5 0.9
C7 1.0 2.5 C8 0.5 0.7 C9 0.5 1.4
CIO 1.3 0.4 Cll 1.5 1.9 C12 2.1 1.8
C13 1.1 2.7 C14 2.4 1.2 C15 2.5 0.8
C16 0.7 2.1 C17 2.2 2.0 C18 1.9 1.4
C19 0.3 N.T. C20 0.9 0.6 C21 2.0 2.5
C22 1.3 1.4 C23 1.2 1.5 C24 1.3 1.0
C25 1.3 1.3 C26 0.9 N.T. C27 2.6 N.T.
C28 0.8 2.2 C29 1.0 1.0 C30 1.2 1.8
C31 1.2 1.3 C32 1.7 1.8 C33 0.9 0.5
C34 1.3 1.5 C35 1.3 0.9 C36 1.0 1.4
C37 0.8 1.3 C38 2.0 1.3 C39 1.3 1.5
C40 1.3 1.7 C41 1.1 1.3 C42 0.7 1.4
C43 1.8 1.7 C44 0.3 1.6 C45 2.0 2.2
C46 1.2 2.4
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Employing the criterion of an SI^.3 as a positive response in
the LTT, 56/66 patients were positive in the 6 day assay and 49/56
in the 7 day assay (fig 3.10). Five patients (P16, P24, P30, P32
and P49) were positive only in the 7 day assay; two patients (P26
and P46) were positive in the 6 day assay and not the 7 day LTT.
Together, the 6 and 7 day assays detected 61/66 (92%) of the
nickel-sensitive patients. None of the controls (0/46) were
positive in the LTT.
The patients not detected by the 6 and 7 day assays were P52,
P53, P56, P58 and P64. Three of these patients (P56, P58 and P64)
had weak positive patch test reactions to nickel sulphate. Patient
P52 gave a strong patch test reaction, but may not have been
detected in the 7 day assay because of the high background value
obtained (See Appendix III, page 181). Cells from all 5 patients
responded against Con A (See Appendix III, pages 181-82).
The significance of differences between patient and control
cells were determined using the student's t-test and are shown in
Table 3.3.
As expected, there were no statistical differences between
patient and control cells incubated in medium (background
proliferation) (0.5 > p > 0.1) and when the cells were incubated
with Con A (p > 0.5). Significant differences were obtained for
nickel sulphate concentrations between 2.5 and 20jug/ml (p < 0.001)
in both the 6 and 7 day assays.
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Fig3.10
DetectionofNickelS nsitivity:Summany ResultsObtainedU ingthLTT (5jug/mlNickeS lphate)
00
Patients 58F,8M
Age=16-75 (MeanAge=33) Controls 32F,14M Age=17-54 (MeanAge=35)
Positive Negative
vhODay6+,7- Dav6~O y7+ (]NotTested
Day67
Summaryofthenumbersickel-s nsitivepatiandon-sensitisedco trolsp itivnega ei the6and7d yLTTsusing5jig/mlNiSO^.
Table 3.3 Significance of Differences Between Patient and Control
Cell Stimulation
DAY 6 DAY 7
Stimulant t df p t df p
Medium 0.718 110 0.1-0.5 0.360 97 > 0.5
10j_ig/ml
Con A 0.668 110 > 0.5 0.384 95 > 0.5
20jjg/ml
NiS04 5.73 93 < 0.001 5.76 86 < 0.001
lOpg/ml
NiS04 8.15 105 < 0.001 7.24 97 < 0.001
5jig/ml
NiS04 8.56 110 < 0.001 7.46 97 < 0.001
2.5pg/ml
NiSO. 7.09 109 < 0.001 6.69 93 < 0.001
CORRELATION BETWEEN PATCH TEST AND LTT RESULTS
The Wilcoxon's Rank Sum Test was used to evaluate the
correlation between patch test scores and stimulation indices
obtained in the the LTT using 5jug/ml of nickel sulphate (shown in
Table 3.1).
The correlation between the patch test scores and the in vitro
results was weak. Correlation coefficients of 0.38 and 0.33 were
obtained for patch test scores with 6 and 7 day results
respectively.
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ACCESSORY CELL FUNCTION OF BLOOD AND EPIDERMAL CELLS
Peripheral blood mononuclear cells include T-cells, B-cells,
monocytes and dendritic cells. To establish the ability of
different cell types to act as accessory cells it was first
necessary to obtain a highly enriched T-cell population with
insignificant accessory cell contamination and consequently
incapable of proliferation in the presence of mitogen or antigen.
Monocytes/macrophages can be isolated by their ability to
adhere readily to plastic or glass surfaces. In addition,
dendritic cells also adhere to surfaces during the first two hours
of incubation, but become detached after 18 hours.
Two methods are commonly used to purify T-cells:-
rosetting with sheep erythrocytes or
passage through nylon wool columns.
Rosetting
In the early 1970's, it was discovered that some human
lymphocytes bind in vitro to sheep red blood cells (SRBC) to form
rosettes . It was suggested that the rosette-forming cells were T-
cells (Wybran and Fudenberg, 1971). In 1973, Weiner e_t al.
reported that neuraminidase treatment of SRBC enhanced rosetting
activity and a year later, Kaplan and Clark (1974) described
another improved procedure for rosetting T-cells by pre-treating
the SRBC with a sulphydryl reagent 2-aminoethyisothiouronium
bromide (AET). After rosetting, the cells are subjected to osmotic
shock to lyse the SRBC.
Nylon Wool Passage
The isolation of murine T-cells by the passage of lymphocytes
through nylon fibre columns at 37°C was described by Julius e_t al.
(1973). B-cells adhere to the nylon fibres and are retained in the
column.
- 83 -
Nylon wool passage has two advantages over SRBC rosetting.
Firstly, the enriched T-cells are not subjected to osmotic shock,
and secondly, the T-cells will not be activated by binding at the
SRBC receptor (CD2).
Enrichment of T-Cells
AET-SRBC rosetting and nylon wool passage were compared in
order to assess the most suitable method of T-cell enrichment for
studies of accessory cell function.
PBM were obtained from blood samples and the plastic-adherent
blood cells were removed (as described on page 52). The plastic-
non-adherent cells were divided into two equal groups. T-cells
were obtained from cells which either were incubated on a nylon
wool column for 1 hour (37°C) and then incubated on glass for
hours at 37®C (page 55), or from cells which were rosetted with
AET-SRBC, isolated from the non-rosetted cells and then subjected
to osmotic shock (to lyse the SRBC), as described on pages 53-54.
T-cells were then incubated with lOjug/ml Con A in a 5 day
proliferation assay. Results (representative of 3 experiments) are
shown in fig 4.1.
As fig 4.1 shows, the T-cells obtained using the rosetting
procedure responded to Con A in the absence of additional accessory
cells whereas the T-cells obtained from passage through nylon wool
did not. Therefore, nylon wool passage followed by glass adherence
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Characterisation of Cell Populations
Antigen presentation requires the presence of MHC II+ cells.
Therefore, to ensure that the T-cell populations obtained were
highly enriched and that cells capable of antigen presentation had
been removed, cells were stained using indirect immunofluorescence
for the expression of MHC II antigens using antibody DA6.231 (anti
HLA-DP, -DQ and -DR) (see page 57). The percentages of cells
expressing MHC class II antigens are summarised in Table 4.1.
Table 4.1 The Expression of MHC II Antigens By PBM, Plastic-
Adherent Blood Cells, Enriched T-Cells and Epidermal Cells
Cell Population DA6.231"1" Cells
Range(%) Mean(%)
PBM 22 7.5-16 11.3
Plastic-Adherent 22 28-72 54.6
Nylon Wool Enriched T 22 0H1o 0.4
Epidermal 6 1.2-3.0 2.2
Previous authors including Braathen (1980) have stated that
enriched T-cells should contain < 1% macrophages and < 5% B-cells.
In the experiments described in this thesis, if > 0.5% T-cells
expressed MHC II antigens, the T-cells were considered to be not
fully enriched.
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The Ability Of Plastic-Adherent Blood Cells To Act As Accessory
Cells
The ability of plastic-adherent blood cells to act as
accessory cells in the presence of lOjng/ml of Con A and 0—lOjag/ml
of nickel sulphate in a 6 day LTT was studied in 18 experiments
using cells from 15 nickel-sensitive patients and in 16 experiments
using cells from 8 non-sensitised controls. Nylon wool enriched T-
£
cells (10 /ml) were incubated with Con A or 5jug/ml of nickel
sulphate in the presence or absence of 10^/ml (10%) plastic-
adherent blood cells. The results were then compared with those
£
obtained using 10 /ml PBM. The data are shown in Appendices V and
VI (pages 187-89). Stimulation indices obtained using Con A and
5;ug/ml NiSO^ are shown in Tables 4.2 and 4.3.
Stimulation of nylon wool enriched T-cells (SI ^3) by Con A
(column 3) or nickel sulphate (column 6) from patients P4b, P20b,
P48a, P51 and P62 (fig 4.2) indicated that in these experiments the
T-cells were not fully enriched. Patient T-cell responses against
Con A and nickel sulphate were reconstituted by the addition of
irradiated plastic-adherent blood cells in 15/18 experiments (eg
P50, fig 4.3). There was no reconstitution of the Con A response
by plastic-adherent blood cells from P41 or reconstitution of the
antigen-specific response by cells from P4a. There was no
reconstitution of both the mitogen- and antigen-specific response
using cells from P9 (fig 4.4) and it is possible that the plastic-
adherent cells from this patient had lost their accessory cell
function during their preparation even though they had suffered no
loss of viability.
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A response against Con A was evident in the nylon wool
enriched T-cells from controls reconstituted with plastic-adherent
blood cells in all of the experiments, with one exception (C27)
which was due to high background proliferation (see Appendix VI,
page 189). T-cell proliferation in the presence of 5jug/ml of
nickel sulphate was absent in all 16 experiments using cells from
controls (Table 4.3 columns 5-7; eg C13a, fig 4.5).
Using a paired t-test, stimulation indices for PBM and T-cells
reconstituted with plastic-adherent blood cells, and stimulated




Stimulation Indices Obtained Using Con A and 5pg/ml Nickel Sulphate
With PBM And Nylon Wool Enriched T-■Cells With Or Without Added
Plastic--Adherent Blood Cells
Patients
lOjug/ml Con A 5jug/ml NiSCX
Pat PBM T T+10%Ad PBM T T+10%A
PI 6.0 1.2 3.6 4.1 N.T. 3.2
P3 70.0 2.5 102.0 23.0 0.5 54.0
P4a 102.0 2.0 15.3 29.0 1.0 1.4
P4b 22.5 3.5 22.0 7.3 1.5 14.0
P9 11.4 1.6 2.8 4.2 0.5 1.8
P12 3.4 0.5 3.5 3.0 0.5 3.9
P14 21.0 2.0 3.4 22.0 0.8 54.0
P18 2.7 1.3 3.1 4.5 1.0 8.3
P20a 5.2 1.2 4.3 5.2 0.5 9.0
P20b 4.4 1.6 3.6 8.9 3.8 12.3
P40 9.7 2.2 6.2 10.8 N.T. 16.6
P41 3.3 1.3 2.1 3.2 N.T. 3.6
P46 3.5 1.6 8.4 3.8 0.9 3.7
P48a 6.7 2.0 6.3 6.5 5.0 8.3
P48b 6.1 1.3 5.7 6.2 1.7 6.2
P50 22.9 2.0 13.6 4.1 1.7 6.0
P51 20.8 2.0 17.5 12.5 7.0 12.6
P62 28.8 14.0 42.9 9.1 10.1 13.7
N.T. = Not Tested
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Table 4.3
Stimulation Indices Obtained Using Con A And 5jug/ml Nickel Sulphate
With PBM And Nylon Wool Enriched T-Cells With Or Without Added
Plastic-Adherent Blood Cells
Controls
lOjug/ml Con A 5jug/ml NiS0;|
Cont PBM T T+10%Ad PBM T T+10%i
C7 88.0 1.3 9.6 1.0 N.T. 1.3
Clla 5.8 1.7 6.6 1.2 0.8 1.1
CI lb 6.0 1.4 4.4 1.3 1.4 1.3
Cllc 8.5 1.9 11.7 2.0 0.5 2.1
Clld 9.0 2.5 8.1 2.8 1.3 1.6
C12a 3.8 2.5 4.9 1.3 N.T. 1.1
C12b 7.4 1.4 5.4 2.7 N.T. 2.7
C12c 19.3 1.5 13.2 1.4 1.0 1.6
C13a 20.6 1.7 19.5 2.3 2.2 2.2
C13b 10.6 1.8 6.4 1.5 N.T. 1.1
C17 76.0 1.1 9.1 1.0 0.8 0.7
C26a 5.6 1.6 9.4 0.9 N.T. 2.7
C26b 9.9 1.1 9.8 2.0 0.8 2.9
C26c 5.3 1.1 4.6 1.8 0.5 1.0
C27 5.4 1.1 2.3 2.6 0.5 1.4
C31 18.3 1.7 30.0 0.4 1.7 1.3
N.T. = Not Tested
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Fig4.2
ReconstitutionfT—CellesponsebyPlastic—AdherentBlo dCell vO h-* IPatient62 cpmx1/1000 100
PBM T T+10%AdherentCells
10jug/mlMediu2.5j /5pg/ ConANickelSulphate
StimulationofPBM,nylowo lenrichedT-cells,andnyl olenrichedl sthddeirradi tplastic- adherentbloodcells(10%)fr mnickel-sensitivepati ntu gme ium,lO g/mlCAan2.5/ l5pg/ NiSO^ina6dayLTT.Resultscpmx10-^(Mean+SD).
Fig4.3
ReconstitutionfT—CellesponsebyPlastic—AdherentBlo dl Patient50 cpmx1/1000 110 vO ts5I|PBM ■HT
T+10%AdherentCells
10jjg/mlMediu2.5 j /5ju ConANickelSulphate
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Fig4.4
ReconstitutionfT—cellesponsebyPlastic—AdherentBloodCell Patient9 cpmx1/1000 KO LO40 30- 20 10- 0T lOpg/ml ConA|IPBM ■■T
T+10%AdherentCells
Medium5pg/ml NickelSulphate
StimulationofPBM,nylonwo lenrichedT-cellsandlenricheT l sddeirradiat dpl stic adherentbloodcells(10%)fr mnickel-sensitivepatieu i gm d um,lO g/mlCoAn5pg/ lNiSO^i6 LTT.Resultsincpmx10"^(M an±SD)
Fig4.5
ReconstitutionfT—CellesponsebyPlastic—Adher ntBloodCell Control13a ConANickelSulphate StimulationofPBM,nylowo lenrichedT-cel s,andnyl olriT l sw thddeirradiaplastic- adherentbloodcells(10%)fr mnon-sensitisedcontrolu gm um,lOpg/mCAa d5pg/NiSO^i6d y LTT.Resultsincpmx10"^(Mean+SD).
The Accessory Cell Function Of Epidermal Cells
Having established a method to investigate the abilities of
plastic-adherent blood cells to act as accessory cells, the
accessory cell function of epidermal cells was investigated. In
these experiments, only a limited number of epidermal cells could
be obtained. Therefore, the 6 day LTT was carried out with 2x10^
PBM/well and also 10^ PBM/well to determine whether fewer
lymphocytes could be used effectively in the assay.
Results from one experiment using cells from a nickel-
sensitive patient (P16) and a non-sensitised control (C24) are
shown in fig 4.6 and Table 4.4. When 10^ PBM/well were incubated
with either 5jug/ml or lOjug/ml of nickel sulphate, the SI obtained
decreased and the patient was not positive in the assay whereas
positive Sis were obtained using 2x10^ cells/well. Therefore,
2x10^ cells/well were used in the epidermal cell reconstitution
experiments.
Table 4.4 Stimulation Indices Obtained using 2x10^ and IP"'
PBM/well in the 6 Day LTT







P16 3.5 4.0 2.5 2.7
C24 1.5 1.3 1.3 1.0
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Fig 4.6
To establish whether 1x10^ cells/well could be used successfully in
the LTT, lxlO5 PBM/well and 2xl05 PBM/well (normally used in the
experiments described in this thesis) from 1 nickel-sensitive
patient and 1 non-sensitised control were incubated with 0-10jag/ml
NiSO^ in the 6 day LTT. Results in cpm x 10" (Mean + SD).
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The Ability of Epidermal Cells to Act as Accessory Cells in the
Presence of Con A
Studies carried out by Braathen and Thorsby (1980) indicated
that epidermal accessory cell function required a T-cell:epidermal
cell ratio of 10:4 (i.e. 40% epidermal cells). Therefore, up to
40% epidermal cells were used in the following experiments to
determine their accessory cell function. Initial experiments were
carried out using cells from control subjects in a 5 day assay with
Con A. As previously described, nylon wool enriched T-cells
(10^) were incubated with lOpg/ml of Con A in the presence or
absence of either 10^ (10%) plastic-adherent blood cells or with
10^-4x10^ (10-40%) epidermal cells and the results compared with
those obtained using PBM. The stimulation indices obtained using
nylon wool enriched T-cells with or without accessory cells and PBM
are shown in Table 4.5.
Table 4.5
Stimulation Indices Obtained Using 10^ PBM or 10% Plastic-
Adherent Blood Cells and 10-40% Epidermal Cells With 10^ Nylon Wool
Enriched T-Cells
Expt PBM T_ T+10%Ad T+10%Ep T+20%Ep T+40%Ep
El 142.0 1.0 23.3 91.5
E2 65.0 2.0 30.0 44.0
E3 18.0 3.0 26.0 6.4 6.0 18.0
E4 10.0 2.0 5.4 4.2 5.0 4.2
The addition of 40% epidermal cells to the T-cells gave a good
reconstitution of the Con A response in the first three
experiments. Reconstitution in the final experiment was similar
when three epidermal cell concentrations (10%, 20% and 40%) were
used. Experiments were then carried out using 40% (and if
possible, 20%) epidermal cells to assess their ability to present
the antigen nickel sulphate to enriched T-cells.
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The Ability of Epidermal Cells to Act as Accessory Cells in the
Presence of Nickel Sulphate
The ability of epidermal cells to present both Con A and
nickel sulphate to nylon wool enriched T-cells was investigated
using cells obtained from 5 patients and 4 controls in a 6 day LTT.
Experimental results are shown in Appendices VII and VIII (pages
190-91). Stimulation indices obtained using mitogen and 5jug/ml
nickel sulphate are shown in Table 4.6. Results from one patient
(P48) and one control (C31) are displayed graphically in figs 4.7
and 4.8.
Addition of both 20% and 40% epidermal cells to the enriched
T-cells reconstituted or enhanced the Con A response in all
patients and controls (Table 4.6, columns 5 and 6) and increased
the mitogenic response of highly enriched T-cells from P48 and C31
in relation to the stimulation of PBM (see figs 4.7 and 4.8). A
T-cell response against nickel sulphate was evident only when cells
from nickel-sensitive patients were used (Table 4.6. columns 7-11;
figs 4.7 and 4.8).
The T-cell responses in the presence of both 20% and 40%
epidermal cells were not significantly different from those
obtained using PBM. The epidermal cells contained approximately 2%
MHC II+ cells in contrast to 40-50% MHC II+ cells in the population
of plastic-adherent blood cells. The experimental finding that 20%
epidermal cells are more effective than 10% plastic-adherent blood
cells in permitting mitogen- or antigen-induced T-cell
proliferation supports the statement by Braathen and Thorsby (1983)
that epidermal accessory cells are more efficient than blood
accessory cells on a per cell basis.
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Fig4.8
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THE ROLE OF MHC II ANTIGENS (HLA-DP, -DQ, -DR) IN T-CELL
PROLIFERATION
It is now well established that antigen-specific T-cell
proliferation requires the presence of antigen presenting cells
expressing MHC II molecules. At present, the human class II MHC is
known to contain three regions encoding for HLA-DP, -DQ and -DR
molecules. Studies to assess the role of these three different
molecules can be carried out using antibodies directed against
particular class II MHC antigens.
Three methods can be employed to determine the effects of
antibodies against cell surface antigens on cell proliferation
(Akiyama et al«, 1985).
(1) Lysis of MHC II+ cells using specific antibodies and
complement.
(2) Pulsing the cells with antibody.
(3) Maintaining the antibody in the culture.
In the following chapter, the role of class II antigens in
permitting cell proliferation was studied using 5 monoclonal
antibodies (details shown on page 61):-




L368 Anti-Beta2microglobulin (used as a negative
control).
With the exception of antibody DA6.231, the antibodies used
were in limited supply. Therefore, a method was needed which
allowed the lowest possible concentrations of antibody to be used.
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(1) Destruction of MHC II"1" Cells Using Antibody DA6.231 And
Complement
The requirement for HLA-DR+ cells for T-cell antigen- or
mitogen-induced proliferation is well documented. Therefore, this
proliferation should be inhibited if antibodies against HLA-DR are
used successfully. In order to show that the antibodies were
having a specific inhibitory effect, it was hoped to obtain 50%
inhibition of the antigen-specific proliferative response.
The destruction of cells expressing MHC II antigens (including
HLA-DR) was attempted using antibody DA6.231 and complement (C*).
Like most monoclonal antibodies, DA6.231 is an IgG antibody
(subclass IgGl) and consequently cannot fix complement directly.
Therefore, PBM were incubated with DA6.231, then rabbit anti-mouse
serum, and finally complement (See Materials and Methods, page 61).
Stimulation indices obtained for the populations of cells
undergoing different treatments with the antibodies and complement
are shown in Table 5.1, together with the percentage inhibition of
the Con A response obtained using untreated cells.
Table 5.1 Inhibition of the Con A Response by Destroying MHC II"1"
Cells with DA6.231 and Complement
+ Reagent SI % Inhib
DA6.231 Rb anti-mlg C'
(a) - - - 4.8 0
(b) - - + 3.3 31
(c) - + - 4.4 8
(d) - + + 3.2 33
(e) + - - 3.5 27
(f) + + - 3.1 35
(g) + - + 4.6 4
(h) + + + 3.2 33
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As shown in Table 5.1, this method did not specifically
inhibit the Con A response; inhibition of the Con A response after
incubation of the cells with the two antibodies and complement (h)
did not differ from some of the inhibitions obtained using cells
incubated with only one (b) or two (d and f) of the three reagents
required.
(2) Inhibition of Cell Proliferation by Pulsing Cells with
Monoclonal Antibodies
Experiments were then carried out to assess the inhibitory
effects of antibodies against MHC II molecules using the method of
pulsing. PBM were incubated with the antibodies for one hour and
were then washed (to remove excess antibody) before being placed in
culture.
Results obtained using cells from 2 nickel-sensitive patients
(P42 and P43) and 1 nickel non-sensitive control (C12) pulsed with
DA6.231 at very high concentrations and then stimulated by Con A
and nickel sulphate are shown in figs 5.1a and 5.1b. Inhibition of
the antigen- and mitogen-induced response was evident using cells
from one patient (P43). However, there was no inhibition of the
response of cells taken from the other patient (P42), even when
3.9jug/ml (3900ng/ml) of DA6.231 was used.
-104-




















PBM were incubated with 0-4]ug/ml of antibody DA6.231 for 1 hour at
room temperature. The cells were washed 3 times with PBS and then
incubated with medium, lOjug/ml Con A (fig 5.1a) or 5jig/ml NiSO^
(fig 5.1b) in the 6 day LTT. Results in cpm x 10" (Mean + SD).
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Results obtained when pulsing PBM with different
concentrations of 4 antibodies (DA6.231, B7/21, Leu 10 and L368)
are shown in Appendices IX.1-IX.8 (pages 192-96). At the lower
antibody concentrations studied, there were no alterations in the
response of cells taken from a nickel-sensitive patient (P38)
against either Con A or nickel sulphate. However, the Con A
response of cells taken from a control individual (C17) was
inhibited (45% inhibition) when 2.6pg/ml of DA6.231 was used.
When the higher concentrations of antibody were used
(Appendices X.1-X.8, pages 197-201), the Con A responses of cells
from both the nickel-sensitive patient (Pll) and the control (C11)
were not inhibited (inhibition < 45%) by any of the antibodies.
However, the antigen-specific response of the patient's cells was
inhibited by 50% by all of the antibodies when used at
concentrations of 2jug/ml, including L368 which is an antibody
directed against MHC I antigens and which was not expected to
affect cell proliferation. Therefore, because of this inhibition
by the control antibody at high concentrations and because of
antibody availability, experiments were carried out to study the
effects on antigen- and mitogen-induced cell proliferation of
maintaining DA6.231 in culture.
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(3) Inhibition of Cell Proliferation by Maintaining Antibody
DA6.231 in Culture
Initial studies were performed to determine the ability of
DA6.231 to inhibit antigen- and mitogen-induced cell proliferation
when the antibody was maintained in the culture system throughout
the 6 day incubation of the LTT. Fig 5.2 shows the results
obtained using cells from two nickel-sensitive patients (P9 and
P10) and two non-sensitised controls (C8 and Cll). Antibody
concentrations greater than 130ng/ml ablated the antigen-specific
responses. These concentrations also permitted some cell
proliferation in the presence of Con A, which probably indicated
that the antibodies were not directly cytotoxic to the cells.
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Fig5.2
InhibitionofCellPr lif ration MaintainingDA6.231iCulture cpmx1/1000 O
oo
Patient9-CoA Patient10-CoA Control8-onA Control11-onA Patient9—NickelSulphate Patient10—NickelSulphate Control8—NickeSulphate Control11—NickeSulphate
012345678901234 Antibody(x1/100g/ml)
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A Comparison of the Effects on Cell Proliferation of Pulsing
Cells with Antibody and Maintaining the Antibody in the Culture
To compare the effects on cell proliferation of pulsing cells
with antibody and maintaining the antibody in the culture system,
PBM from 3 nickel-sensitive patients (P28, P29 and P34) and 1
control (C21) were either pulsed with the monoclonal antibody
DA6.231 at varying concentrations before the addition of 5yug/ml of
nickel sulphate or were incubated with the antibody and 5jug/ml of
nickel sulphate for 6 days in the LTT.
The results obtained are shown in figs 5.3a-5.3d. In these
experiments, PBM from all 3 nickel-sensitive patients pulsed with
the antibody at the higher concentrations (> 520ng/ml) showed more
than 50% inhibition of the antigen-specific cell proliferation.
However, the use of 130-260ng/ml of antibody maintained within the
culture markedly inhibited the antigen-specific response (80%
inhibition). In addition, the viability of the cells after culture
with the antibody for 6 days was determined using trypan blue
exclusion. Cells were more than 90% viable, indicating that the
antibody was not preventing cell proliferation because of
cytotoxicity. An antibody concentration of 260ng/ml was therefore
used in a series of experiments designed to investigate the effects





PBM from 3 nickel-sensitive patients and 1 non-sensitised
control were incubated with 0-2.6jag/ml of DA6.231 for 1 hour at
room temperature and then washed 3 times before lOjug/ml Con A and
5jug/ml NiSO^ were added to the cells and the 6 day LTT was carried
out.
In Culture
The results obtained were compared with those obtained using
PBM from the same patients and control incubated with lOjug/ml Con A
or 5jug/ml NiSO^ and 0-520ng/ml DA6.231 throughout the 6 day LTT.
_ Q
Results in cpm x 10 (Mean +. SD).
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Inhibition of Cell Proliferation by Antibodies Results from the
Inhibition of Accessory Cell Function
Additional experiments were carried out to ensure that the
antibodies against HLA-DR were not inhibiting cell proliferation
either because of cytotoxicity, or by directly preventing either
the proliferation of activated T-cells or the cellular
incorporation of tritiated thymidine. Accessory cell function
takes place within the first 24 hours of culture. Therefore, if
the antibody inhibition is specifically due to the prevention of
accessory cell function, cell proliferation should not be affected
by the addition of antibody to the cells after a few days of
culture, when successful mitogen- or antigen-induced cell
activation should already have taken place.
As stated previously (page 107), the Con A response was not
totally inhibited by the addition of 260ng/ml of DA6.231. As many
of the cells in culture are capable of responding to lOjug/ml of Con
A, it was possible that the anti-HLA-DR antibody may have been
sufficiently cytotoxic to prevent antigen-induced cell
proliferation, whilst not inhibiting totally the mitogen-induced
response. In the following experiments, this was investigated
using cells from 3 patients (P17, P20 and P55) and 3 controls
(C28, C30 and C41). The cells were divided into three groups:-
(a) No antibody in the culture
(b) Antibody added to the culture on day 0
(c) Antibody added to the culture on day 3
and the 6 day LTT was carried out. The results obtained using
antibodies DA6.231, L243 and L368 are shown in figs 5.4 to 5.6.
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DA6.231 (figs 5.4a-5.4f)
lpg/ml of Con A
Maintenance of DA6.231 in the culture for 6 days inhibited the
response of cells from all 3 nickel-sensitive patients and non-
sensitised controls against lpg/ml of Con A; the response was not
affected by the addition of antibody on day 3 in all subjects
except Patient 55 (fig 5.4b).
lOjug/ml of Con A
The response to lOjug/ml of Con A was inhibited when cells from
controls C28, C30 and C41 were cultured in the presence of DA6.231
for 6 days but not when the antibody was added to the cultures on
the third day of incubation (except for C30, Fig 5.4d). Cells
from Patient 55 incubated with lOpg/ml of Con A were not inhibited
by the maintenance of DA6.231 in culture (fig 5.4b).
Medium
Addition of DA6.231 for the 6 days of culture inhibited the
background proliferation of cells from controls C28 and C41.
5pg/ml of Nickel Sulphate
Addition of DA6.231 for the 6 days of culture significantly
inhibited (> 50%) the antigen-specific response of the cells from
all three patients, and this inhibition was absent when antibody
was added to the cells on the third day of culture.
L368 (figs 5.5a-5.5b)
Addition of the control antibody L368 for the whole of the 6
day culture inhibited the response of cells from control C28
against 10/ig/ml of Con A. There was no inhibition of cell
proliferation in the presence of other stimulants, or when the
antibody was added to the cells on the third day of culture.
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L243 (figs 5.6a-5.6d)
lpg/ml of Con A
The maintenance of antibody L243 during the 6 days of culture
inhibited the response against ljug/ml of Con A of PBM from the 4
subjects studied. There was partial inhibition of the response of
cells from Control 41 following the addition of L243 on the third
day of culture (fig 5.6c).
10|ag/ml of Con A
Maintenance of L243 in the 6 day culture did not inhibit the
responses of cells from Patient 55 against ICtyig/ml of Con A (fig
5.6b). Proliferation of the cells from the remaining three
subjects was inhibited (50%) but there was no effect when the
antibody was added on the third day of culture.
Medium
Addition of L243 decreased the background proliferation of the
cells from Control 41.
5jig/ml of Nickel Sulphate
Maintenance of L243 in the culture for 6 days inhibited the
antigen-specific response of cells from nickel-sensitive patients
P20 and P55 (figs 5.4a,b); addition of the antibody on day three of
the culture permitted antigen-induced cell proliferation.
The results of these experiments indicated that the inhibition
seen when 260ng/ml of either DA6.231 or L243 is added to PBM in the
presence of mitogen or antigen and left in the culture for the 6
day period of the LTT, results from an inhibition of accessory cell
function, and not from either antibody cytotoxicity or the direct




PBM from 3 nickel-sensitive patients and 3 non-sensitised controls
were incubated with 1 and lOjug/ml Con A, medium and 5jug/ml NiSO^ in
the 6 day LTT. To assess whether DA6.231 was inhibiting cell
proliferation after T-cell activation, 260ng/ml antibody was added
to the cells before culture (Antibody Day 0) and when the cells had
been incubated for 2 days (Antibody Day 3). Results in cpm x 10""^
(Mean ± SD).
Figs 5.5a-5.5b
PBM from 1 nickel-sensitive patient and 1 non-sensitised control
were incubated with 1 and ICtyug/ml Con A, medium and 5(Ug/ml NiSO^ in
the 6 day LTT. To assess whether L368 could affect cell
proliferation after T-cell activation, 260ng/ml antibody was added
to the cells before culture (Antibody Day 0) and when the cells had
been incubated for 2 days (Antibody Day 3). Results in cpm x 10"^
(Mean + SD).
Figs 5.6a-5.6d
PBM from 2 nickel-sensitive patients and 2 non-sensitised controls
were incubated with 1 and 10jng/ml Con A, medium and 5jug/ml NiSO^ in
the 6 day LTT. To assess whether L243 was inhibiting cell
proliferation after T-cell activation, 260ng/ml antibody was added
to the cells before culture (Antibody Day 0) and when the cells had
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The Role of Different MHC Molecules in PBM Proliferation
The effects on PBM proliferation of five antibodies (DA6.231,
L243, B7/21, Leu 10 and L368) left in the culture in a 6 day LTT
were determined using 0-260ng/ml of antibody. PBM were incubated
with antibody for one hour before either lOjug/ml of Con A or 5jug/ml
of nickel sulphate was added and the 6 day LTT carried out.
The radioactive counts obtained in these experiments are shown
in Appendix XI (Figs XI.1-XI.5, pages 202-6). The percentage
inhibitions of cell proliferation obtained using each of the five
antibodies are shown in figs 5.7-5.11. The ranges of percentage
inhibition of cell proliferation obtained using 260ng/ml of
antibody are shown in Table 5.2.
Table 5.2 Inhibition of Cell Proliferation Obtained using 260ng/ml
of Antibody
Antibody MHC Antigen





% Inhib % Inhib
10jug/ml Con A 5;ug/ml NiSO^
10, +51 - +85










The inhibition of antigen- and mitogen-induced PBM
proliferation using antibodies DA6.231 and L243 against HLA-DR was
dose dependent (figs 5.7 and 5.8); nickel sulphate-induced cell
proliferation was inhibited by more than 82% by 260ng/ml of
antibody. The results obtained using the remaining three
antibodies were more variable; B7/21 (anti-HLA-DP, fig 5.9)
inhibited the antigen-specific response (32-58% inhibition) but did
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not affect mitogen-induced proliferation. The addition of antibody
Leu 10 (anti-HLA-DQ, fig 5.10) had variable effects on raitogen-
and antigen- induced PBM proliferation, producing both inhibition
and stimulation. Finally, the control antibody L368 (anti-beta2~
microglobulin, figs 5.11), had variable effects on the mitogen-
induced proliferation and weakly inhibited (0-27%) the antigen-
specific response.
These experiments indicate that HLA-DR molecules are important
in permitting antigen-specific PBM proliferation and suggest that
the expression of HLA-DP molecules may also be required for
antigen-specific T-cell activation.
-118-
Percentage Inhibition of Con A—Induced Cell Proliferation














Percentage Inhibition of Nickel Sulphate—Induced Cell Proliferation











PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml of DA6.231 (anti-HLA-DP, -DQ, -DR) and
lQ/ug/ml Con A (Fig 5.7a, 4 patients, 4 controls) or 5^ig/ml of NiSO^
(Fig 5.7b, 5 patients) in the 6 day LTT. The percentage inhibition of
proliferation was calculated (1- [(cpm with antibody) / (cpm without
antibody)]) x 100.
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PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml of L243 (anti-HLA-DR) and ICtyug/ml Con A (fig
5.8a, 6 patients, 3 controls) or 5jug/ml NiSO^ (fig 5.8b, 6 patients)
in the 6 day LTT. The percentage inhibition of proliferation was
calculated (1- [(cpm with L243) / (cpm without L243)]) x 100.
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PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml B7/21 (anti-HLA-DP) and lOjiig/ml Con A (fig
5.9a, 6 patients, 4 controls) or 5jag/ml NiSO^ (fig 5.9b, 6 patients)
in the 6 day LTT. The percentage inhibition of proliferation was
calculated (1 - [(cpm with B7/21) / (cpm without B7/21)]) x 100.
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Percentage Inhibition of Con A—Induced Cell Proliferation














Percentage Inhibition of Nickel Sulphate—Induced Cell Proliferation










PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml Leu 10 (anti-HLA-DQ) and 10jag/ml Con A (fig
5.10a, 4 patients, 4 controls) or 5jug/ml NiSO^ (fig 5.10b, 4 patients)
in the 6 day LTT. The percentage inhibition of proliferation was
calculated (1- [(cpm with Leu 10) / (cpm without Leu 10)]) x 100.
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Fig 5.11a













Percentage Inhibition of Nickel Sulphate Induced Cell Proliferation
Antibody L368 (Anti-^-Microglobulin)
PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml L368 (anti-beta2microglobulin) and 10/ug/mlCon A (fig 5.11a, 4 patients, 3 controls) or 5jug/ml NiSO, (fig 5.11b,4 patients) in the 6 day LTT. The percentage inhibition of
proliferation was calculated (1- [(cpm with L368) / (cpm without
L368)]) x 100.
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The Role of MHC Molecules of Different Antigen Presenting
Cells in Accessory Cell Function
It was initially hoped to study the role of epidermal cell MHC
molecules in antigen- and mitogen-induced T-cell proliferation.
However, because of the limited availability of epidermal cells
from nickel-sensitive patients, these experiments could not be
carried out.
A study was possible, however, using plastic-adherent blood
cells as APCs. These accessory cells were irradiated and then
incubated with either DA6.231 (260ng/ml) or L243 (260 or 52ng/ml)
for one hour before the addition of nylon-wool-enriched T-cells and
either lOpg/ml of Con A or 5jug/ml of nickel sulphate.
The results obtained for both antibodies are shown in
Appendices XII (DA6.231 = 3 patients, 3 controls, page 207) and
XIII (L243 = 4 patients, 3 controls, page 208). Results obtained
using cells incubated with DA6.231 (Pll and C12a) and L243 (P20a
and C12d) are shown in figs 5.12-5.15. The percentage inhibition
of cell proliferation by the antibodies is shown in Table 5.3, and
the stimulation indices obtained with and without antibody are in
Table 5.4.
As expected, the addition of 260ng/ml of DA6.231 to PBM
inhibited the antigen-specific response of cells from patients 11
and 51 by more than 80% (see Table 5.3). Inhibition by the
antibody was much weaker (37%) when enriched T-cells from Patient 1
were reconstituted with plastic-adherent blood cells. Inhibition
of the Con A response by 260ng/ml of DA6.231 ranged from 23-87%,
and was less marked when enriched T-cells were reconstituted with
plastic-adherent blood cells.
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Table 5.3 Percentage Inhibition of Cell Proliferation using
Antibodies DA6.231 and L243
lOjig/ml Con A 5jig/ml NiSO^
Ab PBM T +10% Ad PBM T + 10%
(ng/ml) 260 52 260 52 260 52 260
DA6.231
Pat
PI 77 47 83 37
Pll 81 87 88 89








P20a 74 47 65 51 84 34 90 56
P40 79 N.T. 83 N.T. 87 N.T. 96 N.T
P48a 48 25 67 34 88 71 92 68
P50 83 64 76 56 58 42 81 75
Cont
C12d 81 35 84 57
C13b 60 N.T. 75 N.T.
C27 59 24 70 50
N.T. = Not Tested
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The addition of 260ng/ml of L243 also inhibited the
proliferation in response to antigen and mitogen of both PBM and
enriched T-cells reconstituted with plastic-adherent blood cells.
In 3 of the 4 experiments carried out, the proliferation of the
patients' cells in the presence of 5jng/ml of nickel sulphate was
inhibited by more than 80% by 260ng/ml of L243 (Table 5.3).
Addition of 52ng/ml of L243 inhibited the antigen-specific
responses by more than 30%. The higher concentration (260ng/ml) of
L243 induced greater inhibition of the Con A response than an
equivalent concentration of DA6.231; more than 50% inhibition was
evident for cells from the three nickel-sensitive patients and non-
sensitised controls. The Con A response was less affected by
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The background values of cell proliferation were also
decreased by the addition of antibody to the cultures (see
Appendices XII and XIII, pages 207-8). However, the stimulation
indices obtained for cells from 12/13subjects (except Control 12b,
see Table 5.4) incubated with Con A were reduced by the addition of
260ng/ml of either DA6.231 or L243. The stimulation indices
obtained using cells from nickel-sensitive patients cultured with
5)ug/ml of nickel sulphate were also reduced to values less than
three in 6/7 experiments (see Patient 50, Table 5.4).
The results of these experiments indicated that the method
used would be suitable for assessing the role in accessory cell
function of MHC molecules on cells other than blood cells.
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Table 5.4 Stimulation Indices Obtained from Cells Incubated with
DA6.231 and L243 in Culture
Con A NiSO/j
Ab PBM T + 10% Ad PBM T +10% Ad
(ng/ml) 0 260 52 0 260 52 0 260 52 0 260 52
DA6.231
Pat
PI 6 4.9 3.6 2.8 4.1 2.5 3.2 3
Pll 3.4 1.9 3.5 0.9 3.0 1.0 3.9 0.9
P51 20.8 4.0 in•T—1 6.9 12.5 1.2 15.0 1.2
Cont
C12a 7.4 2.9 5.4 4.2 1.5 1.7 1.1 0.8
C12b 20.6 25.7 19.5 14.8 2.7 1.4 2.7 0.9
C13a 3.8 1.8 4.9 3.6 2.3 1.2 2.0 0.5
L243
Pat
P20a 5.2 3.6 5.6 4.3 3.3 4.8 5.2 2.3 6.8 9.0 2.0 9.1
P40 9.7 3.5 N.T. 6.2 1.3 N.T. 10.8 2.6 N.T. 15.8 0.8 N.T.
P48a 6.7 4.2 5.5 6.3 1.0 2.1 6.5 1.0 2.1 8.3 1.4 4.4
P50 22.9 10.3 5.6 13.6 4.5 15.3 4.1 4.7 1.6 6.0 1.6 3.9
Cont
C12d 8.3 1.6 5.6 11.7 4.7 12.2 2.0 0.4 1.0 2.1 0.8 1.1
CI 3b 10.6 8.3 N.T. 6.4 1.8 N.T. 1.5 1.1 N.T. 1.1 1.1 N.T.
C27 5.4 4.3 6.5 2.4 4.1 10.3 2.6 0.5 0.8 1.4 0.7 2.0
N.T. = Not Tested
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DISCUSSION
The aims of the study described were to establish an in vitro
LTT which identified patients with ACD against nickel, and then to
modify the assay to ascertain the accessory cell function of
plastic-adherent blood cells and epidermal cells and the role of
particular MHC II molecules in accessory cell function.
Detection of Nickel Sensitivity using the LTT
An _in vitro LTT to detect nickel sensitivity was first
published more than twenty five years ago (Aspegren and Rorsman,
1962) and a number of modifications recorded since then (see pages
38-41). Not all of the methods described discriminate successfully
between nickel-sensitive individuals and non-sensitised controls.
Antigen concentrations must be neither cytotoxic (Macleod e_t al.,
1970) nor mitogenic to lymphocytes (Svejgaard et_ _al. , 1978; Al-
Tawil ejt _al_. , 1981). In the preliminary studies reported in this
thesis, investigations indicated that nickel sulphate
concentrations greater than 30jug/ml were cytotoxic and that a
concentration of 20;ug/ml of nickel sulphate stimulated cells from
certain non-sensitised individuals. It is unlikely that
transformation of cells taken from "non-sensitised" controls
indicates latent nickel sensitivity (Svejgaard e_t _al_. , 1978)
because 25jug/ml of nickel sulphate has been shown to stimulate cord
blood lymphocytes (Al-Tawil e_t al. , 1981), indicating a weak but
significant mitogenic effect at higher nickel sulphate
concentrations.
Proliferation of cells from nickel-sensitive patients and non-
sensitised controls was therefore determined using 0-20jug/ml of
nickel sulphate and with lOjug/ml of Con A in 6 and 7 day assays.
As expected, cells from patients and controls were equally
stimulated by the mitogen Con A (Svejgard et^ al. , 1978).
Stimulation of cells from nickel-sensitive individuals by nickel
sulphate was often dose dependent, being maximal with a
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concentration of 20jng/ml of antigen in the 6 day assay and lOjug/ml
of nickel sulphate in the 7 day assay. However, the greatest
statistical difference between patient and control cell stimulation
was obtained using 5;ng/ml of antigen in the 6 day assay. The
existence of two groups of nickel-sensitive patients whose cells
respond maximally to either the highest or lowest nickel sulphate
concentrations in the LTT (as described by Gimenez-Camarasa et al.,
1975) was not evident amongst the patients studied using the assay
described in this thesis.
Employing criteria of a stimulation index greater than or
equal to three (Macleod et_ _al., 1970) and a concentration of 5jug/ml
of nickel sulphate in 6 and/or 7 day assays, cells from 61/66 (92%)
patch test positive patients gave a positive response in the LTT;
cells from none of the 43 negative controls responded.
Different antigen concentrations, incubation times and
criteria for positivity have been employed by other investigators
making direct comparisons of results difficult. However, the assay
described in this thesis was more successful at detecting nickel-
sensitive patients than those described by Macleod et al. (1970),
Hutchinson e_t aJ. (1972), Svejgaard e_t _al_. (1978), Macleod e_t al.
(1982) and Res e_t aJ. (1987), the major differences being the
nickel sulphate concentrations employed and the use of only one 6
day assay. Assays carried out for different culture periods may
increase the number of patients detected. Thus, in the experiments
described in this thesis, a greater percentage of the patients
studied using 5jug/ml of nickel sulphate were positive in the 7 day
assay than in the 6 day assay.
False positive results were obtained by Svejgaard ert
al.(1978), Chu £t_ al. (1987) and von Blomberg van der Flier et al.
(1987). These may have been due to the raitogenic effects of higher
concentrations of nickel sulphate used in the assays. False
positive results described by Macleod ejt _al_. (1982) using a lower
antigen concentration were unexpected as previous reports by these
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authors (Macleod _et j_l., 1970; Hutchinson e_t al., 1972) did not
indicate that the concentration of nickel sulphate used in the
assay (14pg/ml) would stimulate cells from non-sensitised controls.
Two assays have been described which were more successful in
detecting nickel-sensitive individuals. Using a range of nickel
sulphate concentrations, Gimenez-Camarasa et al. (1975) found that
cells from 92% of 25 nickel-sensitive patients and none of 10
controls were positive in their 6 day assay. Al-Tawil e_t al.
(1981) detected 15/16 (94%) patients and none of ten controls.
They later reported 100% detection of 45 patients with no false
positive results in 37 controls (Al-Tawil e_t al., 1985b, but their
data was not shown). However, a recent report indicates that the
assay may not be so reproducible (Gilboa et^ ^1_., 1988).
Furthermore, they used rather complicated criteria for positivity
which required three nickel sulphate concentrations (including the
mitogenic concentration of 25pg/ml of nickel sulphate) and a
comparison of the results with those obtained using cells from
controls.
Five nickel-sensitive patients were not detected by the assay
described in this thesis. One patient (P51) had a +++ patch test
reaction and may not have been detected because of the very high
incorporation of tritiated thymidine into unstimulated lymphocytes
taken from this individual in the 7 day assay. Three of the
remaining four patients had weak (+) patch test reactions and may
not have been truly allergic. Of 853 metal workers studied by
Fischer and Rystedt (1985), 4 patients exhibited + reactions
against nickel sulphate, but on retesting none of them gave a truly
allergic reaction. Forman and Alexander (1972) have also described
patients with positive patch tests and negative LTT results who
when recalled were found to have no clinical signs of allergy and
had become patch test negative. Therefore, some + reactions may
not be truly allergic reactions and could be due to mild
irritation.
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A study of six patients indicated that PBM taken from patients
when they first attended the clinic for application of patches did
not have a significantly different response in the LTT to PBM taken
at the time of the day 5 reading. This is in agreement with the
results published by Veien et al. (1979) who found that only oral
ingestion of nickel and not patch testing could increase antigen-
specific T-cell proliferation. This was not described by Al-Tawil
et al. (1985b) who reported increased nickel-specific lymphocyte
transformation using cells from patients after patch testing.
However, they only used cells from two patients and two controls.
In general, however, patch testing may not increase _iri vitro
nickel-specific cell proliferation because nickel is widespread in
the environment and consequently the skin is continuously
challenged with this metal.
Despite the ability of the LTT to detect patients with nickel
sensitivity, correlations between patch test reaction severity and
the stimulation indices obtained in the 6 and 7 day assays were
weak. Low correlation coefficients were also obtained by Al-Tawil
e_t al^. (1985a) who compared results using the in vitro LTT with an
in vivo serial dilution test (in which patients were patch tested
with varying concentrations of nickel sulphate). Discrepancies
between patch test reactions and LTT results may be attributed to
the selection of patients (ie patients who had recently had
dermatitis) (Al-Tawil al., 1985a) and the ability of the antigen
to penetrate through the skin. In addition, the chemicals used in
patch testing and the LTT are seldom obtained from the same source.
Discrepancies between _iii vitro and _rn vivo results may
reflect the limitations of _iii vitro assays. In a true ACD
challenge reaction, antigen is carried from the skin (probably by
epidermal Langerhans cells (Botham et al., 1987)) to the draining
lymph nodes, where there is an expansion of antigen-specific T-
cells. Inflammatory cells (including T-cells, monocytes and
basophils) are then recruited into the site of antigen application.
However, in human in vitro assays, the cells used are usually taken
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from peripheral blood and not from the antigen-reactive site or
draining lymph nodes. Local retention of antigen-specific
lymphocytes at reactive sites and a decreased number of specific
cells in the peripheral blood may result in false negative results
(von Blomberg-van der Flier e_t al_., 1987). Measurement of the
proliferation of cells obtained from an allergic-reaction site
(using a method described by Kapsenberg et al., 1987) may provide a
better correlation with patch test results, but it is clearly
unsuitable for routine clinical use.
Infiltrating T-cells in a nickel sulphate-allergic reaction
are primarily CD4+ (Scheynius _et_ al., 1983; Gawkrodger, 1987). In
the nickel sulphate LTT, the majority of proliferating cells are
CD4+; however, their proliferation requires the presence of CD8+
cells which also slowly proliferate in the culture (Silvennoinen-
Kassinen ej^ al. , 1986). It is not known whether the cells
proliferating in the LTT are of the same phenotype as the T^ cell.
Expression of the T200 protein (CD45) (Morimoto et al. (1985) may
subdivide CD4+ cells into two functional populations, one providing
help in specific antibody responses and the other making IL-2 and
mediating DTH and T-cell proliferation (Janeway ej: al., 1988).
However, experiments to detect this protein were not performed.
Furthermore, the cells present in the in vitro assay are taken from
a blood sample and cannot replace the repertoire of cells capable
of reacting _ln vivo. In addition, the leucocyte separation
procedure depletes the cells of basophils. A T-cell dependent
release of vasoactive amines from mast cells has been described
(Askenase and Van Loveren, 1983) and the resultant inflammation
will contribute to the _iri vivo allergic reaction but will not be
detected by the LTT.
In summary, the LTT using 5jug/ml of nickel sulphate in 6 and 7
day assays with a stimulation index greater than or equal to three
can discriminate reproducibly between nickel-sensitive patients and
non-sensitised controls. However, reactivity of cells in the in
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vitro LIT correlated weakly with the severity of jji vivo patch test
reactions.
Although _in vitro assays cannot mimic exactly an _in vivo
situation, the LTT can be manipulated to study directly particular
aspects of the response. This was done to assess the abilities of
both plastic-adherent blood cells and epidermal cells to act as
accessory cells to purified T-cells in the LTT.
The Accessory Cell Function of Plastic-Adherent Blood Cells and
Epidermal Cells
T-cells were successfully enriched in a number of experiments
using a combination of adherence to glass and plastic and nylon
wool passage. Background proliferation of the cells was decreased
and stimulation by either Con A or nickel sulphate was ablated. In
a small number of experiments, Con A- or nickel sulphate-induced
proliferation of enriched T-cells in the absence of additional
accessory cells indicated the presence of contaminating accessory
cells within the 'T-cell' population. The plastic-adherence step
removed both monocytes and dendritic cells. Passage through nylon
wool depleted cells of B-cells (Greaves and Brown, 1974), further
macrophages and a large proportion of the remaining dendritic cells
(Nussenzweig and Steinman, 1980). A final step of glass adherence
permitted the adherence of monocytes which can readily reattach to
surfaces. Thus, any contaminating cells in the population of
enriched T-cells were probably dendritic cells or B-cells.
However, the presence of 5% B-cells in a T-cell population does not
affect cell proliferation (Braathen, 1980). In the experiments
described in this thesis, less than 1% of MHC II+ cells in the
enriched T-cell population could occasionally mediate a patient T-
cell response to either Con A or nickel sulphate or both,
indicating that the contaminating cells were highly efficient
accessory cells (therefore probably dendritic cells, Van Voorhis
et al., 1983). However, attempts to stain dendritic cells
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specifically using the antibody RFD1 (Poulter e_t_ al^. , 1984) were
unsuccessful.
On average, 55% (range 28-72%) of the plastic-adherent cells
expressed MHC II molecules. Quantitative MHC II expression is
related directly to antigen presentation (Beller, 1984; Kurt-Jones
et al. , 1985). However, two functional subsets may exist within
the MHC II+ monocytes, one mediating antigen-induced proliferation,
the other with the capacity to induce allo-reactive mixed leucocyte
reactions (Raff et al., 1980).
Blood monocytes can present antigens but it is considered
unlikely that ingestion and processing as described for lysozyme or
ovalbumin (Allen and Unanue, 1984; Kapsenberg e_t al., 1986), is
required for small antigens such as nickel. However, Silvennoinen-
Kassinen et al. (1987) have shown that during the first five hours
of culture it is only adherent cells which take up nickel.
Furthermore, immediate uptake (within the first five minutes) was
significantly greater using cells from nickel-sensitive patients
than from controls, although uptake by both patient and control
cells equalised after fifteen minutes.
Addition of plastic-adherent blood cells to enriched T-cells
reconstituted the responses of nickel-sensitive patients' cells to
both Con A and nickel sulphate and of T-cells from non-sensitised
controls to only Con A. In general, SI obtained using T-cells
reconstituted with plastic-adherent blood cells appeared to be less
than those obtained using PBM, but they were not statistically
different. This may reflect the removal of a subpopulation of
cells required for maximum stimulation or the use of an
insufficient number of accessory cells. The latter is unlikely
because, in the experiments described, 10^ plastic-adherent cells
were added to 10 T-cells (10%) and this percentage of adherent
cells has previously been shown to be an optimal concentration in
LTTs using the antigens streptolysin 0 and staphylococcal protein A
(Scala and Oppenheim, 1983). Unfortunately, many authors
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investigating the role of different accessory cells in T-cell
activation have not published stimulation indices obtained using
PBM.
The plastic-adherent blood cells used as accessory cells
contained monocytes and dendritic cells in unknown proportions.
Reports indicate that approximately 5% of monocytes are dendritic
cells (Van Voorhis £t_ _al. , 1983). Differences in the staining of
these accessory cells with antibodies DA6.231 (against MHC II
antigens) and Leu M3 (against a monocyte marker) were minimal (see
page 57); this may have resulted from variability in the staining
and counting technique or have truly reflected the presence of 3%
dendritic cells in the plastic-adherent cell population.
The precise roles of monocytes and dendritic cells in antigen
presenting function have not yet been determined because of an
inability to obtain a population with 100% purity. The
relationship between dendritic cells and monocytes may depend on
the antigen used in the system. Dendritic cells are required for
the initiation of primary immune responses (Van Voorhis e_t al.,
1983) and constitutively express high levels of MHC II molecules.
However, they are weakly phagocytic and do not degrade particulate
antigen (reviewed by Austyn, 1987). Therefore, small numbers of
monocytes are obligatory for the presentation of particulate
antigen by dendritic cells (Kapsenberg et al., 1986). Conversely,
the presence of monocytes may inhibit dendritic cell presentation
of soluble purified protein derivative (PPD) and it is thought that
this inhibition of cell proliferation results from the release of
prostaglandin E2 by monocytes (Bjercke and Gaudernack, 1985).
The ability of blood dendritic cells to present nickel
sulphate to enriched T-cells has been described recently by Res jet_
al. (1987). However their results differ from those previously
reported in that they were unable to detect nickel-specific
lymphocyte transformation using PBM from some nickel-sensitive
patients. These differences may have resulted from the use of an
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assay system which had not been correctly established.
Furthermore, the nickel sulphate concentrations they employed have
been found to be either mitogenic or toxic, both during the
experiments described in this thesis and by other authors
(Svejgaard e_t al_. , 1978; Al-Tawil e_t al_. , 1981). Finally, they
indicated that a population containing monocytes and dendritic
cells could present antigen in very low numbers (less than 5%)
before an autologous mixed leucocyte reaction occurred; this
differs from the results presented in this thesis and from those
described by Braathen (1980), Braathen and Thorsby (1980) and
Rasanen e_t _al_. (1986).
Thus, reports in the literature indicate that plastic-adherent
blood cells do possess accessory cell function in the stimulation
of lymphocytes by both Con A and nickel sulphate. However, in ACD
reactions, it is unlikely that peripheral blood APCs are involved
in initiating the reaction. Evidence suggests that after
epicutaneous application of antigen, epidermal LCs take up the
antigen, leave the skin via the lymphatics and then settle in the
draining lymph node where they maintain a clonal proliferation of
antigen-specific T-cells (Silberberg-Sinakin jet a_l. , 1980; Knight
et al., 1985).
The ability of epidermal cells to mediate Con A- and nickel
sulphate-induced proliferation of T-cells was investigated using
cells from nickel-sensitive patients and controls. Using
immunofluorescence, 2% of the epidermal cells were shown to express
MHC II antigens in contrast to the 55% of MHC II+ cells in the
population of plastic-adherent blood cells. However, 40% (or even
20%) epidermal cells were as effective as 10% plastic-adherent
blood cells in permitting T-cell proliferation in the presence of
10fig/ml of Con A. Indeed, addition of 40% epidermal cells to the
enriched T-cells often enhanced the Con A response. Similar
results have been obtained using guinea-pig T-cells reconstituted
with 20% epidermal cells and stimulated with 5jug/ml of Con A in a 4
day assay (Scheynius et^ al. , 1983).
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Epidermal cells (40% and 20%) also enhanced the responses of
nickel-sensitive patients' T-cells incubated with both 2.5 and
5jag/ml of nickel sulphate. False positive results (Chu e_t al.,
1987) were not obtained in the assay. These findings support work
published by Braathen and Thorsby (1983) who used a much higher
ratio of epidermal cells:T cells (1:1 or 2:1). They showed that
epidermal accessory cells were more potent than monocytes on a per
cell basis. Lower epidermal cell:T cell ratios (ie 20% and 40% as
used in the experiments described in this thesis) produced much
lower stimulation (Braathen, 1980), although it is not known
whether these epidermal cell concentrations fully reconstituted the
T-cell response because results obtained using PBM or T-cells and
monocytes were not published. Irradiated epidermal cells have also
been shown to be more efficient than irradiated PBM at presenting
influenza A and herpes simplex viruses (HSV) (Bagot et al., 1985).
For many years, the LC was considered to be the only epidermal
cell capable of accessory cell function. LCs express MHC molecules
(Rowden e_t _al. , 1977) and produce IL-1 (ETAF) (Sauder ^t al.,
1984). LCs have been enriched using a number of techniques,
including Percoll separation (Scheynius ej^ al_. , 1983) and rosetting
using the LC Fc receptor (Rasanen e_t a_l. , 1986) or 0KT6 (Bjercke £t_
al., 1984). These LC-enriched fractions have been shown to possess
accessory cell function.
A synergistic relationship between LCs and keratinocytes in
accessory cell function was considered when keratinocytes were
shown to produce IL-1 (Sauder e_t al., 1982). Subsequent studies
have shown that keratinocytes express MHC II antigens in
inflammatory conditions or in the presence of gamma interferon
(Basham e_t al. , 1984). These MHC II+ keratinocytes may augment
antigen presentation by LCs (Tjernlund and Scheynius, 1987;
Scheynius et al., 1988), although they are unlikely to have played
a role in the _ln vitro assay employed in this thesis because
suction blisters were obtained from clinically uninvolved sites.
Induction of keratinocyte MHC II molecules probably results from
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the release of inflammatory mediators (including gamma interferon)
by activated cells. It is possible that MHC II expression by
keratinocytes may either maintain or down-regulate an ACD reaction.
At present, the relationship between LCs and blood dendritic
cells is unknown. LCs are derived from the bone marrow (Katz et_
al. , 1979) and therefore may be expected to migrate to the skin
after transport in the peripheral blood. Thus, blood dendritic
cells may be the precursors of LCs.
The capacities of enriched LCs and blood dendritic cells as
APCs have been compared (Bjercke e_t a_l_., 1985a; Res et al., 1987).
Although both cell types present antigens, LCs may be more
effective (Bjercke et al,, 1985a). The reason for this increased
accessory cell function is unknown. If blood dendritic cells are
the precursors of LCs they may be less differentiated and therefore
less efficient than LCs at acting as accessory cells (Kapsenberg ej^
al., 1987). In addition, blood dendritic cells may be precursors
of a number of cell types with different functions; in mice a Thy-
1+ dendritic cell has been described which is also derived from the
bone marrow (Tschachler et_ _al. , 1983; Bergstresser e_t _al_., 1984)
but which may down-regulate the immune response (Bigby et^ al.,
1987). Furthermore, a small population of non-adherent 0KT6+
dendritic cells has been described in the peripheral blood
(Dezutter-Dambuyant e_t _al. , 1984) and these cells may not have been
isolated with the other blood dendritic cells but may be the true
precursors of LCs and possess a similar accessory cell function.
The antigens commonly studied _iii vitro (eg nickel sulphate,
PPD and HSV) are those which are presented to the immune system
after passage through the skin. It is possible that after entry,
the epidermal APCs may form a unique antigen recognisable by the T-
cell but which is not formed by other types of APC. Thus, some
nickel-specific clones derived from nickel-contact dermatitis
lesions and expanded using mitogens, allogeneic cells and IL-2
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recognised nickel only when it was presented by epidermal cells and
not by monocytes and dendritic cells (Kapsenberg ej^ al., 1987).
Finally, differences in the accessory cell functions of
dendritic cells and LCs may result from differences in their
abilities to induce either IL-1 or express MHC II molecules.
Monocytes produce more IL-1 than LCs but are less potent accessory
cells (Rasanen e_t _al., 1986). Therefore, the expression of MHC II
molecules may play a major role in accessory cell function.
Although dendritic cells have a large surface area, LCs may
express 50-100x more HLA-DR molecules than both blood monocytes and
dendritic cells (Bjercke _et^ al_. , 1985b). This increased number of
LC MHC II molecules together with an absence of prostaglandin
secretion may be responsible for the increased accessory cell
function of LCs.
In summary, both plastic-adherent blood cells (monocytes and
dendritic cells) and epidermal cells (probably LCs) from nickel-
sensitive patients and non-sensitised controls could act as
accessory cells in the presence of Con A. These accessory cells
also stimulated the proliferation of T-cells from patients in the
presence of nickel sulphate. The results obtained indicated that
on a per cell basis, epidermal MHC II+ accessory cells are more
efficient than plastic-adherent MHC II+ blood cells. The LTT was
then modified further to investigate the role of the MHC II
molecules in accessory cell function.
Role of MHC II Molecules
The requirement for MHC II+ cells in antigen-specific T-cell
proliferation is well documented (Habu and Raff, 1977; Thorsby et
al., 1982). At present, three classes of MHC II molecules have
been described in man, HLA-DP, -DQ, -DR. The molecules comprise an
alpha and a beta chain. The HLA-DR alpha chain is constant in all
individuals but amino acid differences are present in various HLA-
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DP and -DQ alpha chain alleles, and all three beta chains are
polymorphic. The variation in the molecules may result from
requirements of alpha/beta pairing; the HLA-DR alpha and beta
chains are apart on the genome and are more likely to be separated
during recombination. Therefore, the alpha chain may be constant
because it must be capable of joining a number of beta chains
(Trowsdale, 1987).
It has been suggested that variability in the MHC II chains
may reflect their functional differences, with different class II
loci governing particular subsets of T-cells (Trowsdale, 1987). It
was the aim of some of the experiments described in this thesis to
determine whether or not expression of any of the three human MHC
II molecules was important to accessory cell function in nickel-
induced allergic contact dermatitis.
The requirement of 'self' MHC II molecules in antigen
presentation was discovered by Rosenthal and Shevach in 1973 when
they showed that antigen presentation by guinea pig macrophages
could take place only if the T-cells came from an animal of the
same strain. Similar experiments using cells from humans are
harder to carry out because of the highly polymorphic nature of the
MHC II antigens which can cause an allogeneic mixed leucocyte
reaction, and the necessity to tissue type patients. However, a
few studies have been described which show the necessity of 'self'
HLA-DR molecules in antigen presentation. These employ antigen-
specific T-cell blasts because addition of allogeneic cells to
antigen-specific T-cell blasts produces a low mixed leucocyte
reaction (MLR) in comparison to that obtained using resting T-
cells.
In 1980, Bergholtz ejt _al_. showed that at least one HLA-DR
determinant must be shared (or serologically cross-react) between
the T-cell and macrophages to permit antigen-specific T-cell
proliferation. Later, similar studies indicated that HLA-DR was
not the only restricting molecule for antigen-specific T-cell
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proliferation. HLA-DQ was shown to restrict presentation of PPD
and HSV (Berle and Thorsby, 1982), and HLA-DQ and/or HLA-DP
restricted presentation of contact sensitisers including nickel
sulphate (Al-Tawil e_t al., 1985c). A number of experiments have
shown that any of the three MHC II molecules can act as restriction
elements for T-cell proliferation (Qvigstad e_t al. , 1984).
As well as using tissue typed cells, the role of the different
MHC II molecules in accessory cell function can be assessed using
antibodies against one or more of the three MHC II molecules, and
this method was used in the experiments described in this thesis.
Attempts to remove cells bearing MHC II molecules with the
monoclonal antibody (DA6.231) and complement were unsuccessful.
This probably resulted from the inability of the antibody to fix
complement (because of its IgG subclass). Pulsing cells (ie
incubating the cells with antibody and then washing off excess
antibody before culturing the cells) partially inhibited nickel-
specific cell proliferation when high concentrations of DA6.231
(6.5]ug/ml) were used. Previous reports had indicated that pulsing
cells with 2-2Ctyig/ml of anti-MHC II antibody could inhibit antigen-
or alloantigen-induced cell proliferation (Romagnani jit al., 1985;
Kalil and Wollraan, 1983). However, pulsing cells with antibodies
against HLA-DR may not always inhibit accessory cell function. MHC
II antigens may be shed from the cell surface preventing persistent
inhibition. Furthermore, pre-treatment of accessory cells may not
interfere with the resynthesis and expression of class II antigens
(Akiyama et al., 1985).
The limited availability of monoclonal antibodies prevented
their use in the high concentrations required for cell pulsing.
Therefore, an assay system was used in which lower concentrations
of anti-MHC II antibodies remained in culture with the cells for
the 6 day incubation.
-146-
Antibodies were added to the cultures at a concentration of 0-
260ng/ml. These concentrations were acceptable for an experiment
maintaining the antibody in culture, 100 ng/ml of soluble antibody
being able to prevent antigen-specific cell proliferation (Muchmore
et al., 1982).
HLA-DR
Addition of antibodies DA6.231 (anti-HLA-DP, -DQ, -DR) and
L243 (anti-HLA-DR) directly inhibited the nickel-specific response
of cells from sensitised patients and this inhibition was dependent
on antibody concentration. These results support previous work
suggestive of an important role for HLA-DR molecules in antigen
presentation. Thorsby e_t a_l. (1982) showed strong inhibition of
the PPD-specific proliferative response using antibodies against
HLA-DR haplotypes common to autologous and allogeneic monocytes
used as accessory cells. Pulsing monocytes with anti-HLA-DR for
varying periods of time also inhibits antigen-specific
proliferation (Muchmore _et_ al. , 1982; Gerrard e_t al. , 1983;
Romagnani ejt al., 1985). Finally, abolition of HLA-DR+ cells with
rabbit anti-HLA-DR and complement removes antigen-specific
proliferation (Braathen and Thorsby, 1980).
Antibodies against HLA-DR initially bind to monocytes,
macrophages, dendritic cells and B-cells. However, after
activation, T-cells express MHC II antigens. The addition of
antibodies two days after culture (after antigen presentation had
taken place) did not affect T-cell proliferation and indicated that
the decreased stimulation obtained in the presence of antibody did
not result from direct inhibition of T-cell proliferation.
Furthermore, cell viability was maintained after 6 days incubation
with DA6.231 and L243 indicating that the antibodies were not
cytotoxic.
Complement was present in the autologous plasma. Antibody
L243 is of an IgG subclass capable of fixing complement.
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Therefore, it is possible that some of the HLA-DR+ cells were
destroyed by antibody L243 and complement fixation. Antibody L243
gave slightly better inhibition of proliferation than DA6.231 but
this could have been due to other reasons such as antibody
affinity and avidity and the additional binding of DA6.231 to HLA-
DP and HLA-DQ molecules.
The role of epidermal HLA-DR molecules in _iti vitro
presentation of nickel sulphate was not investigated. It is likely
though that they play a significant role in the induction of nickel
sensitivity. Langerhans cells have been shown to express high
numbers of HLA-DR molecules (Bjercke e_t al., 1985) and previous
studies have shown that the removal of HLA-DR+ cells with antibody
and complement ablates antigen-specific T-cell activation (Braathen
and Thorsby, 1980). Furthermore, experiments using tissue typed
cells have shown that (like monocytes) epidermal cells and
allogeneic T-cells must share at least one HLA-DR determinant to
permit antigen-specific T-cell activation (Berle e_t a_l., 1982).
The roles of the other MHC II molecules in antigen
presentation were less clearly defined by the experiments described
in this thesis.
HLA-DP
The antibody B7/21 against HLA-DP appeared to inhibit the
nickel-specific response only weakly. This inhibition may not have
been specific as inhibitions greater than 50% were not always
obtained. However, they were greater than those obtained using the
'control' antibody against beta2microglobulin.
Antigen (influenza)-specific proliferation by an HLA-DP
restricted T-cell clone has been described (Eckels e_t al_., 1983).
It is possible that only a few of the nickel-specific cells in the
LTT were HLA-DP restricted, resulting in a weak inhibition of cell
proliferation by B7/21. In addition, the percentage of cells
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expressing HLA-DP molecules may have been very low. Neppert (1986)
has shown that the staining of plastic-adherent cells (monocytes)
with this antibody is about a quarter of the density shown by B-
cells and concluded that HLA-DP may not be important in the
functioning of monocytes. However, dendritic cells, which are
considered to be highly efficient accessory cells, may express high
levels of HLA-DP molecules when they have been maintained in
culture for 24 hours (Brooks and Moore, 1988). Therefore,
expression of HLA-DP molecules may have occurred later during the
culture, permitting antigen-specific activation of HLA-DP
restricted T-cells with an expected peak thymidine uptake on days 8
and 9 of culture, making inhibition of this proliferation less
noticeable on day 6 which was the culture period used during these
experiments.
HLA-DP antigens were discovered using HLA-A, -B, -C, -D and -
Dw identical cells in the primed lymphocyte transformation test
(Shaw ^t al_., 1980). Using primary and secondary lympho-
proliferative responses, HLA-DP+ activated T-cells appear capable
of inducing suppressor cells in normal lymphocyte populations and
it has been suggested that these HLA-DP antigens may play a
critical role in the negative feedback of the cellular immune
response (Pawelec et_ al., 1984).
Thus, the type of cell expressing particular class II antigens
may be as, or more, important than the presence of the molecules
themselves. The role of epidermal cell HLA-DP molecules in in
vitro nickel presentation has not yet been investigated. The
observation that keratinocytes express HLA-DR (L243+) and HLA-DP
(B7/21+) in a 48 hour nickel sulphate patch test reaction but not
in an irritant reaction (Gawkrodger, 1987) may indicate an
important role for keratinocyte HLA-DP expression in the induction,
maintenance or suppression of an ACD reaction. Clearly, further
work is required both _in vitro and _rn vivo before the exact roles
of HLA-DP molecules in accessory cell function can be determined.
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HLA-DQ
Using the assay method described, antibody Leu 10 (anti-HLA-
DQ) appeared to have no overall effects on nickel presentation.
The results obtained were variable but further experiments could
not be carried out because of antibody availability.
As described for B7/21, it is possible that Leu 10 had no
effect on antigen presentation because an insufficient number of
APCs were expressing HLA-DQ. After culture for 24 hours, monocyte
expression of class II molecules decreases. However, dendritic
cells may start to express a high density of HLA-DQ molecules on
their cell surfaces which are maintained for at least 8 days
(Brooks and Moore, 1988). In 1983, Gonwa e_t _al. described an HLA-
DQ+ adherent cell subset which is responsible for the presentation
of Candida albicans and is more efficient than an HLA-DQ subset in
the stimulation of an autologous mixed lymphocyte reaction (AMLR),
and it has been suggested that this results from the presence of
dendritic cells in the HLA-DQ+ population (Brooks and Moore, 1988).
Conversely, there is evidence to suggest that HLA-DQ molecules
are important in the induction of suppressor cells. In 1980,
Fainbom e_t _al. showed that T-cells activated by mitogens or
allogeneic cells for 11 or 23 days produced suppression when they
were added to mitogen activated cultures. More than 40% of the
CD8+ cells expressed MHC II antigens. Furthermore, the suppression
could be abrogated either by the removal of the CD8+ cells or the
addition of anti-HLA-DQwl antibody (Festenstein and Oilier, 1987).
HLA-DQ molecules on APCs may also be important in the activation of
suppressor cells. Streptococcal cell wall antigen (SCW) and
Schitosoma japonicum antigen (Sj) initiate poor immune responses in
certain individuals because of the control exerted by an immune
suppression (Is) gene in linkage disequilibrium with HLA-DR2-Dwl2-
DQwl (Hirayama ^t_ _al., 1986). Experiments using antibodies
against MHC II haplotypes including HLA-DR2 and HLA-DQwl have shown
that the HLA-DR2 molecule presents the two antigens to CD4+ cells.
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However, this response is suppressed by suppressor T-cells
controlled by the HLA-DQwl molecule (Hirayama e^ , 1987). A
full _Ln vitro response takes place when either CD8+ cells are
removed or anti-DQwl is added to the culture (Hirayama e_t al.,
1986).
Particular HLA-DQ molecules may therefore play a very
important role in regulating the immune response by activating
suppressor cells. However, it is unlikely that they play such a
significant role in the induction or absence of nickel sensitivity.
As seen in certain autoimmune diseases, population and family
studies of nickel-sensitive patients have indicated a possible
relationship between the incidence of nickel sensitivity and HLA-B
haplotypes (Walton et_ al_., 1986), but a relationship with MHC II
molecules has not been described.
Mitogen-Induced Cell Proliferation
The requirement of MHC II molecules in mitogen-induced T-cell
proliferation is less well defined. Experiments have been
described in which T-cells proliferated in the presence of mitogen
and a class II~ cell line (Bekoff £t_ al_., 1985). In this thesis,
antibodies against HLA-DR (DA6.231 and L243) inhibited Con A-
induced cell proliferation, but this inhibition was weaker than
that seen in nickel-specific proliferation. In preliminary
experiments, increased concentrations of DA6.231 did inhibit the
Con A response more successfully, but an antibody concentration was
chosen which did not totally abolish the mitogenic response because
this helped to indicate that the cells were capable of
proliferation in the presence of the antibody. The antibody
against beta2microglobulin did not affect Con A-induced cell
proliferation; antibodies against HLA-DP and HLA-DQ had variable
effects on Con A-induced cell proliferation and were inconclusive.
These results differ from those reported by Gerrard ej^ al.
(1983) and Akiyama et al. (1985) who showed that the monoclonal
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antibodies they used against MHC II molecules do not affect Con A-
induced cell proliferation. Gerrard e^_ a_l. (1983) used the same
antibody (L243) as described in this thesis. However, they pulsed
the cells with antibody rather than allowing the cell to incubate
with antibody throughout the culture period. It is possible that
some of the antibody was shed from their accessory cells and that
MHC II molecules were re-expressed, permitting Con A-induced cell
proliferation. Although Akiyama et al. (1985) were unsuccessful at
inhibiting mitogen-induced cell proliferation using monoclonal
antibodies, some inhibition was obtained using rabbit antisera
against class II molecules. These antisera would have contained
antibodies against a number of determinants on MHC II molecules.
However, their monoclonal antibodies, being so specific, may not
have recognised an epitope important in antigen presentation.
These reports illustrate that significant differences can be
obtained depending on the different antibodies used.
In the experiments described in this thesis, the antibody
against beta2microglobulin did not affect Con A-induced cell
proliferation. This is at variance with the results of Akiyama £t_
al. (1985) who described inhibition of mitogen-induced cell
proliferation using antibodies against both MHC I antigens and
beta2microglobulin. They suggested that both class I and class II
antigens play a crucial role in the events resulting in
proliferation after interaction with lectins. However, the results
in this thesis and the finding that mitogenic lectins specifically
bind to MHC II molecules (Kiraura and Ersson, 1981) make their
explanation unlikely. It is, however, possible that the different
antibodies used in these two studies reacted with different
determinants on the beta2microglobulin.
Mechanisms of Inhibition
In conclusion, the experiments described in this thesis
indicate that antibodies against HLA-DR can inhibit antigen-
specific (and in some circumstances, mitogen-induced) cell
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proliferation. However, the mechanism of this inhibition is
presently unknown. T-cell activation requires a number of signals
and has a number of stages. Therefore, the antibodies against
class II molecules could exert one or many effects to prevent cell
proliferation.
A number of mechanisms of inhibition have been investigated.
Palacios (1982) showed that IL-2 production was arrested by the
addition of anti-class II molecules, which indicated that T-cell
activation and proliferation is stopped before IL-2 production, RNA
and DNA synthesis and mitosis. Inhibition of the production of IL-
1 (the 'first messenger' in accessory cell function) by the
antibodies is unlikely as addition of exogenous IL-1 does not
restore antigen-specific T-cell activation (Gerrard et_ al_., 1983).
Finally, the addition of certain antisera against HLA-DR may induce
CD8+ cells which non-specifically suppress the antigen-specific
proliferation of cloned T-cells (Lamb et al., 1982). However, this
is unlikely because the antigen-specific response can be restored
by adding monocytes to cultures previously inhibited by the
addition of monocytes pulsed with anti-HLA-DR (Gerrard _et al.,
1983).
The finding that pulsing cells with anti-MHC II antibodies
inhibits antigen presentation by cells already coated with antigen
indicates that anti-MHC II antibodies do not inhibit antigen
binding or processing by the APC (Pawelec eit_ al., 1985). Binding
of immunogenic antigen to MHC II molecules has been described
(Babbitt _et_ al_. , 1985) and it is thought that the antigen must
associate with an MHC II molecule for recognition by the T-cell
receptor. Furthermore, a nickel binding fraction from PBM has been
described which is a protein with a molecular weight similar to
that of the HLA-DR beta chain (Silvennoinen-Kassinen et al., 1987).
If this nickel binding molecule is shown to be part of the HLA-DR
molecule, the antigen recognised by the antigen-specific T-cell
receptor may comprise nickel bound to the HLA-DR beta chain.
Therefore, it is probable that the anti-MHC II antibodies inhibit
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T-cell proliferation by sterically blocking the MHC II- antigen
complex which is recognised by the T-cell receptor.
General Conclusions and Areas to Extend the Work
The 6 and 7 day LTTs using 5jag/ml of nickel sulphate and an SI
greater than or equal to 3 is an excellent and relatively simple in
vitro method for detecting nickel sensitivity; cells from 92% of
nickel-sensitive patients were positive in at least one of the
assays, compared with none of the cells from the non-sensitised
controls. This _iri vitro assay may ultimately be suitable for
replacing patch testing as a method for establishing nickel
sensitivity.
Although the assay was capable of detecting nickel
sensitivity, there was a weak correlation between _rn vitro
stimulation and patch test reaction severity. With co-operation
from patients and clinicians, it may be possible to correlate
results obtained in the LTT with disease activity (and not just
patch test reactivity) over a long time period to establish whether
stimulation in the LTT reflects the patient's clinical presentation
of ACD to nickel. Furthermore, a study of CD4 + and CD8+ cells
could be carried out to establish whether suppressor cells directly
play a role in the quiescence of the disease. Previous work by
Silvennoinen-Kassinen e_t al. , 1986) suggested that it is the CD4 +
cells which are proliferating in the assay system. Examination of
other markers expressed by the cells in vitro (including the T200
marker (Morimoto _et_ al. , 1985 )) may provide further information
about the type of CD4+ cells activated in the culture. These
results could then be compared with the histological identification
of the same markers in nickel-allergic patch test reactions.
Enriched T-cells were obtained from PBM using a three-stage
procedure. Further analysis of the CD4+ and CD8+ cells in the
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remaining T-cell population may indicate whether a particular T-
cell subset had been removed.
Both plastic-adherent blood cells and epidermal cells from
nickel-sensitive patients were capable of acting as accessory cells
in the presence of Con A and nickel sulphate in the LTT. Cells
from non-sensitised controls reacted only against Con A. The
ability of enriched blood dendritic cells and LCs to present nickel
sulphate to enriched T-cells have been described (Res et_ al.,
1987). Establishment of a method which can efficiently isolate
those cells with dendritic morphology from samples of blood and
epidermal cells would enable the use of these enriched cells as
accessory cells in the modified LTT described in this thesis.
The role of HLA-DP, -DQ and -DR displayed on PBM was
investigated by studying the effects on accessory cell function of
monoclonal antibodies against the three MHC II molecules. The
results obtained suggested that HLA-DR was necessary for accessory
cell function. The availability of the antibodies limited the
experiments which could be performed and these studies should be
extended. Furthermore, different monoclonal antibodies against any
one of the MHC II molecules may recognise different determinants.
Therefore, it is possible that the use of a larger battery of
monoclonal antibodies may indicate which determinants on an MHC II
molecule are necessary for recognition by the T-cell. However,
different antibody affinities and avidities will confound the
results obtained. Finally, nickel sulphate is presented to T-cells
after passage through the skin. The experiments described have
shown that epidermal cells from nickel-sensitive patients can
activate autologous enriched T-cells _in_ vitro. The role of the
three MHC II molecules expressed by the epidermal cells should be
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-SensitivePatie sUsing6And7DayLTT 5jag/ml2.u NiS04 16.6+41 0 1 9.0+14.9 26.0+611.4 2 26.0+615 1 5 18.0+13 5 2 8.3+39 4 1 26.2+214 0 3 6.7+22 0 0 12.8+16.6+0 13.1+26.8+ 40.2+322 7 1 2.9+11 8 0 29.0+32 5 11.7+23.9lOjug/mlMedium ConA 20+64.2+2.3 N.T.N.T. N.T.N.T. 9+54.2+1.6 N.T.N.T. 10+22.8+1.9 8+14.4+2.1 17+20.4+0.1 12+13.0+1.4 17+33.3+1.3 N.T.N.T. N.T.N.T. 13+22.4+1.2 N.T.N.T.
DAY7
20pg/mllO NiS04 68.0+1847 8 5 N.T. N.T. N.T.22.2+6 N.T. 37.4+105 2 2 59.1+9102+12 36.0+340.1 9 50.1+641+10 44.7+103 5+8 N.T. N.T. 67.1+643.3+10 N.T.
































































































2.5;ug/ml NiS04 8.5+1 6.0+1 10.5+3 9.3+5 21.6+2 14.3+3 7.0+0 12.5+2 31.9+4 I.8+0 8.7+2 II.5+1 25.9+3 41.2+6
10jug/mlMediu ConA 25+3.9+1.2 60+63.8+0.6 74+43. +0.6 N.T. 46+57.9+2.3 24+44.2 2 11+7.4+1 49+1012.1+1 56+24.3+1.5 21+2.8+0.1 15+32.6+0.8 36+59.2+1.9 4+11.5+0.7 16+18.2+1.7
DAY7
20jug/mllOj+ NiSO^ 34.9+1130 0 2 30.3+626 0 4 29.7+434.0 3 N.T. 98.0+13101 20 52.5+666.2 7 64.9+555.7+1 45.9+749.3+15 51.2+39 .1 4 11.1+18.9+1 28.1+436.4 48.6+732 2 4 19.4+148.4 5 67.6+874.8+11
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2.5pg/ml10 lMediumju5pg/)ug/ l NiS04ConA 7.1+18+1 4.5+17+1 6.5+014+2 6.7+121+3 27.8+39+1 10.2+110+3 16.6+16+0 5.9+18+1 13.7+3N.T. 26.6+36+13.8+1.013.5+1 8.7+2.415.4+1 4.7+2.015.0+2 4.4+1.415.8+1 4.8+1.56.7+1 3.2+1.710.1+2 6.9+0.436.1+4 6.1+1.021.6+3 4.0+1.8N.T. 3.3+0.232.9+320.8+34 2 20.4+117 9 3 16.5+35 6 4 17.1+25 6 18.0+620.9 2 24.6+531 1 6 28.4+53 7 15.8+48.7+2 37.6+81 3 2 51.6+538.4 8
16.8+1 15.7+3 10.6+1 12.7+2 17.9+5 20.7+5 19.2+4 8.3+1 22.3+3 21.5+6
N.T.
=NotTested




















































































































































































































































































































































































































































































































































































































































































AppendixVProliferationfPBMandEnricheT-CellsW toithouAdd dPlastic-Adh r ntBl d CellsinthePresenceofArNick lSulphat PatlOfig/mlMediu ConAPBM
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AppendixV(continue )ProliferatiofPBMa dEnrichT-CellsWitorithoutAddedPlastic-Ad rent BloodCellsinthePres nceofCoArNick lSulphat PatlOjug/mlMediu ConAPBM
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Inhibition of Cell Proliferation. Pulsing with Anti-MHC II
PBM from 1 nickel-sensitive patient and 1 control were pulsed
with antibodies against the MHC molecules (ie incubated with the
antibodies for 1 hour at room temperature and then washed 3 times).
lOpg/ml Con A (Figs a) and 5jug/ml NiSO^ (Figs b) were then added to
the cells and the 6 day LTT carried out. Results in cpm x 10 ^
(Mean £ SD).
Fig IX.1
Patient's PBM + 0-2600ng/ml DA6.231 (anti-HLA-DP, -DQ, -DR)
Fig IX.2
Control's PBM + 0-2600ng/ml DA6.231
Fig IX.3
Patient's PBM +0-1100ng/ml B7/21 (anti-HLA-DP)
Fig IX.4
Control's PBM + 0-1100ng/ml B7/21
Fig IX.5
Patient's PBM + 0-1560ng/ml Leu 10 (anti-HLA-DQ)
Fig IX.6
Control's PBM + 0-1560ng/ml Leu 10
Fig IX.7
Patient's PBM + 0-800ng/ml L368 (anti-beta2microglobulin)
Fig IX.8
Control's PBM + 0-800ng/ml L368.
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FigIX.2a
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FigIX.4a














































































Inhibition of Cell Proliferation. Pulsing with Anti-MHC II
PBM from 1 nickel-sensitive patient and 1 non-sensitised
control were pulsed with antibodies against the MHC molecules (ie
incubated with the antibodies for 1 hour at room temperature and
then washed 3 times). lOpg/ml Con A (figs a) and 5jug/ml NiSO^
(figs b) were then added to the cells and the 6 day LTT carried
out. Results in cpm x 10""^ (Mean + SD).
Fig X.l
Patient's PBM + 0-6550ng/ml DA6.231 (anti-HLA-DP, -DQ, -DR)
Fig X.2
Control's PBM + 0/6550ng/ml DA6.231
Fig X.3
Patient's PBM + 0-2100ng/ml B7/21 (anti-HLA-DP)
Fig X.4
Control's PBM + 0-2100ng/ml B7/21
Fig X.5
Patient's PBM + 0-3200ng/ml Leu 10 (anti-HLA-DQ)
Fig X.6
Control's PBM + 0-3200ng/ml
Fig X.7
Patient's PBM + 0-2010ng/ml
Fig X.8



























InhibitionofNickelSulphate-InducedC lProlif ration Pulsing-AntibodyDA6.231 cp.x1/1000Patiient1 80 70
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FigX.2a


























InhibitionofConA—InducedellProlif rati Pulsing-AntibodyB7/21 cpax1/1000 80Control11 1310210 Antibody(no/dl)
FigX.4a
InhibitionofNickelSulp ate-InducedC llProlifera ion Pulsing-AntibodyB7/21 Control11cpax1/1000 1310210 Antibody(ng/al)
FigX.4b






















InhibitionofNickelSulphate—InducedC llProl feration Pulsing-AntibodyLeu10 Patient11
ngX.5b
■x1/1000 80T 70f- * 80r 40L f 20r1
200032
Antibody{no/ il
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FigX.6a
0200032 Antibody(hf/.l)
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Inhibition of Con A—Induced Cell Proliferation
Antibody DA6.231 (Ant i-HLA-DP, -DQ, -DR)
cpm x 1/1000
Antibody (ng/ml)
Inhibition of Nickel Sulphate-Induced Cell Prolferation
Antibody DA6.231 (Anti-HLA-DP, -DQ, -DR)
Antibody (ng/ml)
PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0—260ng/ml DA6.231 (anti—HLA-DP, -DQ, -DR) and lOpg/ml
Con A (Fig XI.Ia, 4 patients, 4 controls) or 5^ig/ml NiSO^ (Fig XI.Ib, 5
patients, 3 controls) in the 6 day LTT. Results in cpm x 10 (Mean).
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PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml L243 (anti-HLA-DR) and lOjug/ml Con A (Fig
XI.2a, 5 patients, 3 controls) or 5jtig/ml NiSO^ (Fig XI.2b, 6 patients, 2
controls) in the 6 day LTT. Results in cpm x 10 ^ (Mean).
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0 50 100 150 200 250 300
Antibody (ng/ml)
PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml B7/21 (anti-HLA-DP) and 10pg/ml Con A (Fig
XI.3a, 6 patients, 4 controls) or 5pg/ml NiSO^ (Fig XI.3b, 6 patients, 2
controls) in the 6 day LTT. Results in cpm x 10"^ (Mean).
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Inhibition of Con A—Induced Cell Proliferation
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Inhibition of Nickel Sulphate—Induced Cell Proliferation
Antibody Leu 10 (Anti-HLA-DQ)
cpm x 1/1000
Fig XI.4b








PBM from nickel-sensitive patients and non-sensitised controls were
incubated with 0-260ng/ml Leu 10 (anti-HLA-DQ) and lO^g/ml Con A (Fig
XI.4a, A patients, 4 controls) or 5jug/ml NiSO^ (Fig XI.4b, 4 patients, 2
controls) in the 6 day LIT. Results in cpm x 10 (Mean).
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50 100 150 200 250 300
Antibody (ng/ml)
PBM from 4 nickel-sensitive patients and 3 non-sensitised controls were
incubated with 0-260ng/ml L368 (anti-beta2microglobulin) and 10pg/ml Con
A (Fig XI.5a) or 5jug/ml NiSO^ (Fig XI.5b) in the 6 day LTT. Results in
cpm x 10"3 (Mean).
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NiSO^ 1.5+0 N.T. N.T.
T-Cells+10%Plastic-AdherentCells
Pat P20a
19+2
6.5+0
9.2+1
4.4+1.1
2.0+0
1.9+1
39.7+4
3.9+1
17.3+3
P40
29+8
4.8+1
N.T.
4.6+1.1
3.6+0
N.T.
73.1+6
3.0+1
N.T.
P48a
26+3
8.5+1
17.2+2
4.1+1.0
1.9+0
2.5+0
34.1+1
2.6+1
10.9+2
P50
60+6
14.5+1
26.1+2
4.4+0.7
3.2+1
1.7+0
26.6+5
5.0+1
6.6+2
Cont C12d
46+5
7.5+0
19.5+4
3.9+1.3
1.6+0
1.6+0
8.1+1
1.3+0
1.8+0
N.T.=otTested
C13b
14+4
3.5+1
N.T.
2.1+0.6
1.9+0
N.T.
2.4+1
2.2+1
N.T.
Resultsincpmx10
C27
41+8
12.1+2
20.5+3
17.3+2
2.9+0
2.0+0
23.4+1
1.9+0
3.9+1
(mean+SD)
